JOSH GREEN, M.D. GOVERNOR KE KIA'ĀINA



STATE OF HAWAI'I | KA MOKU'ĀINA O HAWAI'I DEPARTMENT OF ACCOUNTING AND GENERAL SERVICES | KA 'OIHANA LOIHELU A LAWELAWE LAULĀ

OFFICE OF ENTERPRISE TECHNOLOGY SERVICES | KE'ENA HO'OLANA 'ENEHANA P.O. BOX 119, HONOLULU, HAWAII 96810-0119

February 19, 2025

The Honorable Ronald D. Kouchi President of the Senate and Members of the Senate Thirty-Third State Legislature State Capitol, Room 409 Honolulu, Hawai'i 96813 The Honorable Nadine K. Nakamura Speaker and Members of the House of Representatives Thirty-Third State Legislature State Capitol, Room 431 Honolulu, Hawai'i 96813

Aloha Senate President Kouchi, Speaker Nakamura, and Members of the Legislature:

Pursuant to HRS section 27-43.6, which requires the Chief Information Officer to submit applicable independent verification and validation (IV&V) reports to the Legislature within ten days of receiving the report, please find attached the report the Office of Enterprise Technology Services received for the State of Hawai'i, Department of Health, BHA Integrated Case Management System Project.

In accordance with HRS section 93-16, this report may be viewed electronically at <u>http://ets.hawaii.gov</u> (see "Reports").

Sincerely,

Christine M. Sakuda Chief Information Officer State of Hawai'i

Attachments (2)



Hawaii BHA Integrated Case Management System Project – Phase 4

IV&V Report for the period of January 1 – January 31, 2025

Final Submitted: February 14, 2025



Solutions that Matter

Agenda

Executive Summary IV&V Findings & Recommendations

Appendices

- A Rating Scales
- B Inputs
- C Project Trends
- D Acronyms and Definitions
- E List of Production Defects





The project is progressing well with the continued enhancements to the INSPIRE system, including the new AER functionality that has completed user acceptance test (UAT). Fast Healthcare Interoperability Resources (FHIR) has now been successfully deployed to production following delays caused by various factors.

Automated regression testing remains on hold due to challenges with testing tools and BHA project team constraints. Existing scripts remain unrepaired, impacting test productivity and quality. The project is set to resolve these issues and intends to bring in additional resources to assist with automated testing, which could increase testing efficiency.

Lack of clarity around contractual terms and conditions and whether story points should apply to defect fixes persists between BHA and the systems integrator (SI); discussions are planned to resolve these issues.

The SI is progressing the AER solution toward completion in accordance with project requirements. DDD has confirmed to IV&V that the SI's AER team has successfully designed and demonstrated dashboards that are both functional and visually appealing. With UAT complete, the AER solution is being enhanced with new requirements to fully align with BHA's expectations. SI and BHA are actively exploring improvements, including new user requests, user stories, and test cases.

In previous reports, IV&V raised concerns regarding the production system restart process. It should be noted that the restart happened once and has not reoccurred. However, IV&V remains concerned about the lack of governance around production system restarts as well as defect management, Calculator defects and resource constraints challenges that could affect the project's progress.



Nov	Dec	Jan	Category	IV&V Observations	
Y	R	Y	Sprint Planning	Sprint Reviews and Demos are currently ad hoc, with the project team proposing to add Calculator and "copy forward" functionalities. The SI demonstrated AER Analytics functionality in December 2024, and the demos have been valuable for DDD in validating requirements and expectations. While requirements have been addressed, some INSPIRE discrepancies have emerged during testing. The upcoming reviews and demos will be key to resolving these issues, aligning expectations, and refining the approach. The team is exploring the best way to integrate the new functionalities. BHA is satisfied with the backlog prioritization. However, CAMHD is concerned that gathering feedback from a broader user base could lead to additional requests without proper prioritization. IV&V recommends BHA implement a structured feedback	
					management process with a prioritization framework to ensure new requests align with project goals. DDD has scheduled the next product backlog meeting on Monday, 2/2/2025, and IV&V will be invited to attend.
G	G	G	User Story (US) Validation	There are no active findings in the User Story (US) Validation category, which remains Green (low criticality) for this reporting period. IV&V will continue to monitor the US development and validation process in upcoming reporting periods.	
Y	Y	Y		Regression testing for R4.10 is scheduled from 1/29/2025 to 2/5/2025, with one defect identified (view on the DDD supervisor dashboard). CAMHD will conduct a mix of manual and automated testing, while DDD will focus on manual testing. To support future Phase 4 releases, the project plans to onboard a Tosca automated regression testing SME, with work set to begin on 3/1/2025. Additionally, the SI is preparing to conduct regression testing on AER functionality for the AER project.	
ww.pub	liccons	Iltinggrou	Test Practice Validation	IV&V has requested a walkthrough of the INSPIRE testing process since October 2024, but SI has not yet been able to provide it. SI will continue collaborating with BHA to support the ongoing progress of INSPIRE testing. To aid future Phase 4 releases, the project plans to onboard a Tosca regression testing SME starting 3/1/2025. UAT for AER functionality is complete, with defects being addressed. Some AER test deliverables are still in progress, and BHA and IV&V are reviewing the remaining items.	

	Executive Summary				
Nov	Dec	Jan	Category	IV&V Observations	
Y	×	>	Release / Deployment Planning	 BHA is working to resolve issues with missing web resources and workflows related to R4.9 deployment. The R4.10 go-live is scheduled for 2/6/2025. After several delays caused by various factors, the SI completed FHIR development and deployed FHIR to production on 1/29/2025. IV&V will continue monitoring the deployment quality of R4.10, FHIR, Mid Sprint Deployment (MSDs), and the AER solution. DDD is working to confirm final approvals, allowing the digitization initiative to proceed with the SI. The project may restart in Spring 2025. Meanwhile, DDD has paused further development on planned improvements to an existing process, which previously took approximately 15 days to complete, as the current SharePoint site cannot handle the anticipated volume of 2.5 million digitized documents without a redesign of its hierarchy. 	



Nov	Dec	Jan	Category	IV&V Observations	
0	G	G	On-The-Job- Training (OJT) and Knowledge Transfer (KT) Sessions	This category remains Green (low criticality) for the January reporting period with no active findings.	
G	G	G	Targeted KT	This category remains Green (low criticality) for the January reporting period. IV&V will continue to monitor.	
G	G	G	Project Performance Metrics	There are no project performance metrics to report for the January reporting period. IV&V will keep this category's criticality rating Green (low criticality) and will continue to monitor.	
G	G	G	Organizational Maturity Assessment (OMA)	This category remains Green (low criticality) for the January reporting period. There are no outstanding findings in this category, and IV&V will continue to monitor.	



YYYProject ManagementThe R4.10 go-live is scheduled for 2/6/2025, with 21 unresolved medium-severity production defects. BHA is prioritizing higher-priority tasks, which has delayed resolution. IV&V recommends that the project have discussions around utilizing tools like SonarQube for continuous code inspection and quality improvement. After several delays caused by various factors, the SI completed FHIR development and deployed FHIR to production on 1/29/2025. The AER solution go-live is set for 2/21/2025. IV&V will continue monitoring the quality of R4.10, FHIR, MSDs, and the AER solution.YYProject ManagementDuring this period, there continues to be a delay in creating Azure DevOps (ADO) tickets for defects. IV&V has raised concerns about the non-adherence to the Defect Management process. IV&V, BHA, and the SI will continue working together to identify process gaps and agree on the next steps.The vendor has built the AER solution in accordance with project requirements and is actively working toward its completion. DDD informed IV&V that the SI's AER team has successfully designed and demonstrated both functional and visually appealing dashboards. The AER solution that has completed UAT and is being enhanced with new requirements to allow BHA to address unreported AERs or conduct reliable investigations. Key insights, such as provider reporting trends and unreported AER tracking, are currently unavailable. Some new requirements will be ready by go-live, while others will be implemented post-launch.	Oct	Nov	Dec	Category	IV&V Observations
	R		Y	-	 production defects. BHA is prioritizing higher-priority tasks, which has delayed resolution. IV&V recommends that the project have discussions around utilizing tools like SonarQube for continuous code inspection and quality improvement. After several delays caused by various factors, the SI completed FHIR development and deployed FHIR to production on 1/29/2025. The AER solution go-live is set for 2/21/2025. IV&V will continue monitoring the quality of R4.10, FHIR, MSDs, and the AER solution. Resource constraints continue challenging the project, but steps are being taken to optimize resources. During this period, there continues to be a delay in creating Azure DevOps (ADO) tickets for defects. IV&V has raised concerns about the non-adherence to the Defect Management process. IV&V, BHA, and the SI will continue working together to identify process gaps and agree on the next steps. The vendor has built the AER solution in accordance with project requirements and is actively working toward its completion. DDD informed IV&V that the SI's AER team has successfully designed and demonstrated both functional and visually appealing dashboards. The AER solution that has completed UAT and is being enhanced with new requirements to allow BHA to address unreported AERs or conduct reliable investigations. Key insights, such as provider reporting trends and unreported AER tracking, are currently unavailable. Some new requirements will be ready by go-live,



Nov	Dec	Jan	Category	IV&V Observations
Y	Y	>	Resource Management	IV&V was informed that some cross-training has occurred, but concerns remain about the lack of knowledge transfer for critical tasks, particularly for the provider and customer portals. While a limited amount of knowledge transfer occurred concerning the provider portal, more comprehensive cross-training could be beneficial to mitigate risks and ensure operational continuity. DDD plans to onboard a Tosca Automated Regression Testing SME to address resourcing issues and improve training, with work set to begin on 3/1/2025.

As of the January 2025 reporting period, Fifteen (15) open findings were updated – Eleven (11) Medium Issues, two (2) Medium Risks, one (1) Low Issue, and one (1) Preliminary Concern spread across the Release/Deployment Planning, Test Practice Validation, Sprint Planning, Project Management, Resource Management, and Schedule Management assessment areas are currently open.

Open Risks/Issues by Category/Preliminary



Assessment Categories

Throughout this project, IV&V verifies and validates activities performed in the following process areas:

- Sprint Planning
- User Story Validation
- Test Practice Validation
- Release / Deployment Planning
- On-the-Job Training (OJT) and Knowledge Transition (KT) Sessions
- Targeted Knowledge Transition (KT)
- Project Performance Metrics
- Organizational Maturity Assessment
- Project Management
- Resource Management



Sprint Planning

#	Key Findings	Criticality Rating		
31	 Medium Risk: A lack of regular Sprint Reviews and Sprint Demos will likely lead to misalignments between delivered work and stakeholder needs. Finding Update: The Sprint Reviews and Demos are currently being conducted ad hoc. In recent discussions, the project team has proposed incorporating both the Calculator functionality and the "copy forward" functionality into the process. The SI demonstrated AER Analytics functionality in December 2024, and the demos have been valuable for DDD in validating requirements and expectations. Although DDD has worked through the requirements, some INSPIRE discrepancies have emerged during joint testing meetings. The upcoming Sprint Reviews and Demos will provide an opportunity to address these discrepancies, align expectations, and refine the approach as they move forward. The project team is actively exploring how to integrate these new functionalities into the reviews and demos to ensure a smooth and efficient process. 	M		
Recommendations				
According to Agile Best Practices, IV&V recommends including Sprint Reviews and Demos in future releases (R4.2 and onwards). At the end of each sprint, conduct a sprint review meeting to demonstrate the completed work to stakeholders and gather feedback. Use this feedback to refine and reprioritize the product backlog. For a two-month sprint, IV&V recommends having more than one (1) demo during the sprint.				
Create a stakeholder register to identify all stakeholders. List their identification, assessment, and classification. Review the register regularly to plan appropriate stakeholder engagement.				
Foster active participation from users and stakeholders during both Sprint Reviews and Sprint Demos. Emphasize the value of iterative feedback to guide development and ensure that user needs are consistently met.				



IV&V Findings & Recommendations Sprint Planning (cont'd)

Recommendations	Status
Establish standardized communication protocols for both Sprint Reviews and Sprint Demos. Encourage teams to deliver concise and informative progress reports, including achievements, challenges, and plans. This will enhance stakeholder engagement and project transparency.	In Progress
Institute a structured documentation process for Sprint Reviews and Sprint Demos. Document key decisions, action items, and insights from each session to ensure accountability and to support ongoing process improvement.	In Progress



IV&V Findings & Recommendations Sprint Planning (cont'd)

#	Key Findings	Criticality Rating
41	 Medium Risk: The absence of separate dedicated product backlog review meetings can lead to unclear priorities, misalignment with stakeholders, inadequate refinement, and an increased risk of scope creep. Finding Update: BHA remains satisfied with the backlog prioritization. However, CAMHD, having conducted surveys and user group interviews in 2019 and 2020, is concerned that gathering feedback from a broader user base might lead to additional requests without proper prioritization. DDD mentioned that the next product backlog meeting is scheduled for Monday, 2/2/2025, due to current team availability and ongoing commitments. Additionally, IV&V will be invited to attend these backlog meetings. 	M

Recommendations	Status
CAMHD and DDD implement a structured feedback management process with a prioritization framework to ensure that all new requests are thoroughly evaluated and aligned with project goals before being added to the backlog.	
Separate dedicated product backlog review meetings (during Sprints) would allow clarifying any ambiguities or uncertainties, re-prioritization, estimation and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items mid-Sprint would have to be taken.	Open
IV&V recommends scheduling separate dedicated product backlog review meetings (during Sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design, development, and implementation (DDI) of the next release(s).	Open



Test Practice Validation

#	Key Findings	Criticality Rating	
2	 Medium Issue: As a result of regression testing not being consistently performed, production releases are breaking existing functionality in the production environment. Finding Update: Regression Testing for R4.10 is scheduled from 1/29/2025 to 2/5/2025. One defect (view on the DDD supervisor dashboard) has come out of regression testing. CAMHD will conduct a mix of manual and automated testing, while DDD will focus on manual regression testing. To support future Phase 4 releases beyond R4.10, the project plans to onboard a Tosca automated regression testing are being reviewed, with plans to commence work on 3/1/2025. For the AER project, the SI is preparing to conduct regression testing on AER functionality. 	M	
Recon	nmendations	Status	
To ensure effective Tosca testing, it is crucial for both divisions to align on a unified resource allocation strategy. Given the limited availability of resources, open communication and consensus-building are essential for optimizing tester utilization. By collaborating to prioritize testing efforts, share critical test cases, and identify overlapping areas, the divisions can achieve comprehensive regression testing without overburdening a single resource. This collaborative approach will balance workloads, streamline processes, and enhance test coverage, minimizing delays and bottlenecks. Ultimately, it will enable both divisions to efficiently meet their testing objectives.			
A balanced approach that combines manual and automated regression testing to ensure broad test coverage and flexibility.			



IV&V Findings & Recommendations Test Practice Validation (cont'd)

Recommendations	Status
Having board(s) in Azure DevOps or a document on SharePoint that provides information about the status of regression testing automation, to facilitate visibility and transparency to BHA project personnel and stakeholders.	In Progress
Schedule priorities should be reevaluated by distributing the work according to the resource bandwidth. This will ensure that the schedule is not impacted and that the work is done efficiently between regression testing and Golden Record (GR) tasks.	In Progress
Pursue and complete additional formal training in Azure DevOps and Tricentis for test automation as soon as possible and complete efforts to automate the two primary regression test scripts.	In Progress
Determine if current regression testing timeframes are adequate, and if not, add more time to the pre-production regression test efforts for all release deployments.	In Progress



IV&V Findings & Recommendations Test Practice Validation (cont'd)

#	Key Findings	Criticality Rating	
40	 Medium Issue: Insufficient testing processes can lead to poor-quality software, project delays and extended user acceptance testing. Finding Update: IV&V has been requesting a walkthrough of the INSPIRE testing process since 10/2024, which the SI has not delivered. IV&V will continue discussions with BHA to ensure progress is made in advancing the SI's INSPIRE testing efforts. To support future Phase 4 releases beyond R4.10, the project plans to onboard a Tosca automated regression testing Subject Matter Expert (SME). The plans and timeline for Tosca automated regression testing are being reviewed with plans to commence work on 3/1/2025. UAT for AER functionality is complete, with the SI addressing defects identified during testing. Some AER testing deliverables, for example, test results, remain incomplete, while BHA and IV&V are reviewing other deliverables. 	M	
Recommendations			
IV&V has requested an overview of the testing process, with a focus on process such as tracking test coverage and requirements traceability.			
A Stakeholder Register helps identify and understand all project stakeholders, ensuring needs are met and risks are managed through effective communication. A RACI matrix clarifies roles and responsibilities, improving collaboration, decision-making, and resource management, which are all critical for the success of IT projects.			
Identify stakeholders (output is Stakeholder Register) and develop a RACI matrix for testing.			
Review the overall testing process and implement any needed improvements identified.			



IV&V Findings & Recommendations Release / Deployment Planning (cont'd)

#	Key Findings	Criticality Rating
39	 Low Issue: Due to on-going deployment processes and technical execution issues, the Project may continue to encounter defects and challenges, e.g., when releases are in production or in meeting projected timelines for production and non-production deployments. Finding Update: R4.9 encountered deployment issues, prompting the creation of a defect in ADO. BHA is actively working to resolve these issues involving missing web resources and workflows. The R4.10 go-live is scheduled for 2/6/2025. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. IV&V will continue to monitor the deployment quality of R4.10, FHIR, any MSDs, and the AER solution. 	
Rec	Recommendations	
The project should consider automating deployments for resource savings, increased efficiency, consistency, faster time to market, improved collaboration and reliability, scalability, version control integration, and rollback capability.		Open
Ensure there are adequate and qualified resources to support the current deployment processes. This may require support from RSM resources to provide assistance and knowledge transfer for some more complex deployment components.		Open



IV&V Findings & Recommendations Release / Deployment Planning (cont'd)

Recommendations	Status
As appropriate, consult with RSM on best practices that BHA could employ to support deployment.	Open
Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments.	Open
Request assistance from the RSM Solution Architect in reviewing deployment scripts to double-check for accuracy and completeness before commencing deployment activities.	Open
The Project Team should consider evaluating potential changes to improve/enhance existing processes and communications to address current release/deployment shortfalls.	Open
IV&V recommends performing a Root Cause Analysis (RCA) in collaboration with RSM for the continued concerns surrounding environment differences.	Open
IV&V recommends updating the Project's Configuration Management Plan to address the current needs of the Project. This should include specific checklists geared at ensuring repeatable promotional processes by DOH.	Open
Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed.	Open
Ensure an operational and fully functional test environment is available to effectively conduct end-to-end regression testing prior to deploying a release to production.	Open
Develop a plan to institutionalize the execution of smoke testing for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities.	Open

Release / Deployment Planning

#	Key Findings	Criticality Rating
43	Medium Issue: Execution time for the process for updating DDD SharePoint folders was unacceptable. Finding Update: DDD is working to confirm final approvals to allow the digitization initiative to move forward with the SI, and the project may restart in Spring 2025. Meanwhile, DDD has paused further development on planned improvements to an existing process, which previously took approximately 15 days to complete, as the current SharePoint site cannot handle the anticipated volume of 2.5 million digitized documents without a redesign of its hierarchy.	M
Rec	ommendations	Status
IV&\	/ recommends doing an impact analysis, e.g., downstream impact.	Open
enco	/ recommends that DDD puts on hold any development utilizing Power Automate for the performance issue ountered in production (marked "TBD" in finding #14 related to "SharePoint Bulk Flows still running") related User Stores, e.g., "Changes to DDD folders," and defects.	Open
IV&\	/ recommends evaluating other feasible options, e.g., leveraging SharePoint tools and best practices.	Open
A pro	oject issue should be opened to identify and manage the resolution of this issue.	Open



Project Management (cont'd)

#	Key Findings	Criticality Rating
14	 Medium Issue: Due to multiple quality concerns, the project may continue to face impactful system defects. Finding Update: The R4.10 go-live is scheduled for 2/6/2025. Currently, 21 unresolved production defects remain, all of medium severity (refer to appendix E for a list of unresolved production defects). The SI indicated that BHA prioritizes higher-priority tasks, delaying the resolution of lower-priority defects. Efforts are underway to address these issues. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. IV&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 	M
Recon	nmendations	Status
The pr	nmendations oject have discussions around utilizing tools such as SonarQube for continuous inspection of code quality stablishing a source code quality threshold to maintain high-quality, secure, and maintainable code.	Status Open
The pr and es The pr	oject have discussions around utilizing tools such as SonarQube for continuous inspection of code quality	
The pr and es The pr reduce	oject have discussions around utilizing tools such as SonarQube for continuous inspection of code quality tablishing a source code quality threshold to maintain high-quality, secure, and maintainable code.	Open



Recommendations	Status
Evaluate existing project staff skills and experience levels to ensure they meet BHA support requirements.	In Progress
Perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected.	In Progress



#	Key Findings	Criticality Rating
	Medium Issue: Performance bottlenecks with the INSPIRE production environment may result in low productivity and poor user experience.	
33	Finding Update: Microsoft completed the DDD performance test and submitted its report, showing similar results between MAX and INSPIRE. IV&V has received and reviewed the performance test report. However, the Provider Portal's performance declined as user volume increased to 500. IV&V recommends conducting performance testing at least annually to ensure system stability.	M
Rec	ommendations	Status
IV&V recommends: BHA execute a performance test during the development of R4.6 (planned completion 5/20/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality		In Progress
	duct load and performance testing for each release that has significant new features/functionality, e.g., ulator-related transactions.	Open
Create a plan for comprehensive performance testing and address any performance bottlenecks.		Open
Have the benchmark assessments done annually and implementation of Azure App Insights for Power Platform.		Open
	cute test scripts that measure the run-time for execution of long-running transactions. E.g., Calculator tionality/transactions and monitoring results over time.	Open



#	Key Findings	Criticality Rating
42	Medium Issue: Lack of effective governance and communication among stakeholders can have significant negative impacts on a project in several ways.	M
42	Finding update: The SI's response is that the project is in a staff augmentation phase, and BHA now owns the project and decides where the SI puts its effort.	
Rec	ommendations	Status
Establish a mutual understanding of the contractual terms and conditions: BHA and the SI have discussions to align on a shared understanding of the contractual terms and conditions for the INSPIRE project.		Open
esca	Ite a Governance Structure: Implement a governance structure that defines decision-making processes, Iation procedures, and accountability mechanisms. Clarify how decisions will be made, who has authority, how issues will be resolved.	Open
and	elop a Stakeholder Registry, RACI Matrix, and Stakeholder Engagement Plan: Identify key stakeholders develop a plan to engage them throughout the project lifecycle. Tailor communication strategies to address needs and preferences of different stakeholders, ensuring their active involvement and support.	Open
invol	rly Define Roles and Responsibilities: Clearly outlining the roles and responsibilities of each stakeholder ved in the project, would ensure that everyone understands their duties and how they contribute to the ect's success.	Open



Recommendations	Status
Encourage Open Communication and Feedback: Foster a culture of open communication and feedback where stakeholders feel comfortable sharing their thoughts, concerns, and suggestions. Encourage constructive dialogue and actively seek input to improve decision-making and problem-solving. Keep stakeholders informed about project progress, milestones, and key developments through regular updates and progress reports. Highlight achievements, challenges, and any changes to the project plan or scope.	Open
Resolve Conflicts Promptly: Address conflicts and disagreements among stakeholders promptly and professionally. Encourage dialogue, active listening, and compromise to find mutually acceptable solutions that support project goals.	Open
Manage Expectations: Manage stakeholders' expectations by setting realistic timelines, budgets, and deliverables. Foster a culture of transparency about project constraints and risks and proactively communicate any changes or deviations from the plan.	Open
Evaluate and Adapt: Continuously evaluate the effectiveness of governance and communication processes and adjust as needed. Solicit stakeholders' feedback to identify areas for improvement and continuously refine your approach.	



#	Key Findings	Criticality Rating
	Medium Issue: There is a lack of stakeholder alignment on cost tracking, federal financial participation allotments, and claims management.	
45	Finding update: Discussions between IV&V, BHA, and Med-QUEST continue to address challenges in tracking federal financial participation allotments and managing claims submissions. Efforts are underway to define a structured process to guide resolution.	M
Reco	ommendations	Status
IV&V recommends that stakeholders establish a structured process to ensure alignment and guide resolution.		Open



#	Key Findings	Criticality Rating
46	 Medium Issue: Neglecting the established defect management process could lead to lost/forgotten defects, user frustration, and could slow resolution of similar defects in the future. Finding Update: During this reporting period, there continues to be a delay in creating tickets in Azure DevOps (ADO) for defects. IV&V remains concerned about the project's deviation from the Defect Management process. IV&V, BHA, and the SI will continue discussions to identify process gaps and determine the next steps. 	M
Rec	ommendations	Status
1. Se impo 2. Ta 3. Co assu 4. Ke incre	/ recommends to: end communications to the project stakeholders to clarify the defect management process and the ortance of logging all defects. ake steps to assure current and new users understand how to report and/or log defects. onsider designating a defect management lead or champion to oversee adherence to the process and are all defects are logged. eep stakeholders informed about defect status, priority, impacts, and resolution timelines. This could ease awareness of the importance of logging defects. iscuss ways to improve the defect logging and management process with the SI and come up with a plan to ove.	Open

#	Key Findings	Criticality Rating
47	 Medium Issue: The lack of a governance process for restarting production systems can impact service availability and frustrate end-users and hinder accountability. Finding Update: When an issue requiring a production Portal restart occurred only once, certain project stakeholders convened to discuss and implement the necessary steps. IV&V recommends documenting the actions taken during that meeting as part of the process for production system restarts. Documenting processes and procedures removes ambiguity and ensures a common understanding among stakeholders. 	M
Reco	Recommendations	
 IV&V recommends BHA 1. Develop standard procedures for system restarts, including pre-checks, step-by-step instructions, and post-restart verifications. 2. Require formal approvals before initiating a restart, especially for INSPIRE, and document all actions in a centralized system. 3. Define clear escalation paths for when restarts do not go as planned, including identifying contacts for technical support and management approval for additional interventions. 4. Automate Restart Procedures where possible. 5. The governance process is established, it should be effectively communicated to the project team. 6. Provide stakeholders with a clear explanation of the reason for the restart and the lessons learned, while documenting the restart details in the defect record. 		Open



#	Key Findings	Criticality Rating
48	Preliminary Concern: Some AER project requirements are reliant on data provided by external partners (e.g., Dept. of Human Services (DHS)).Finding Update: IV&V will close this issue as this issue has been resolved.	Closed



#	Key Findings	Criticality Rating
49	Medium Issue: Multiple AERs for a single episode and false positives. New Finding: The vendor has built the AER solution in accordance with project requirements and is actively working toward its completion. DDD has informed IV&V that the SI's AER team has successfully designed and demonstrated functional and visually appealing dashboards. The AER solution has completed UAT and is being enhanced with new requirements to allow BHA to address unreported AERs or conduct reliable investigations. Key insights, such as trends in provider reporting of adverse events, the number of unreported AERs identified, month-to-month tracking of unreported AERs, and which AERs were created for the unreported AERs, remain unavailable. Some new requirements will be ready by go-live, while others will be implemented post-launch.	M



IV&V Findings & Recommendations Schedule Management

#	Key Findings	Criticality Rating
	Preliminary Concern: There is uncertainty around the scheduling, trainee groupings, and access to training materials for upcoming training sessions.	
50	New Finding: BHA has requested the SI for a complete updated AER project schedule which is yet to be delivered. It is essential for the project team to review training materials in advance to ensure they are properly aligned with the distinct needs of each trainee group. Given the differences in the users' dashboards, users will not be trained together, necessitating the reservation of specific times for each group. Furthermore, the SI vendor is prepared to engage in discussions and provide a preview of the materials that have already been developed. This preview will be valuable for refining content, ensuring it is relevant, and confirming that the materials meet the requirements of each user group.	



IV&V Findings & Recommendations Resource Management

#	Key Findings	Rating	
34	 Medium Issue: A shortage of BHA project resources could lead to reduced productivity and project delays. Finding Update: IV&V was informed that some cross-training had been conducted, but concerns remain regarding the insufficient knowledge transfer for critical tasks. While a limited amount of knowledge transfer occurred concerning the provider portal, it was highlighted that more comprehensive cross-training could be beneficial, particularly for the provider and customer portals. This would help reduce the risks associated with knowledge gaps and ensure continuity in operations, especially in the event of key personnel unavailability. DDD plans to onboard a Tosca Automated Regression Testing Subject Matter Expert (SME) to address the resourcing issue and improve cross-training. The plans and timeline for Tosca automated regression testing are being reviewed with plans to commence work on 3/1/2025. 	M	
Rec	ommendations	Status	
Utilizing peer-to-peer knowledge sharing, allowing experienced team members to informally share their expertise during team meetings. Additionally, creating internal documentation that outlines best practices and processes for developing security policies would serve as a self-service resource for the team.			
DDD and CAMHD have further discussions to optimize resource utilization between the two divisions.			
BHA	should explore options for offloading project team members' daily responsibilities to other staff.	In Progress	
BHA	should work quickly to create new positions and receive State approval.	In Progress	
BHA should identify tasks and duties that they can ask the SI to assume, as permitted by the contract, which are presently being handled by BHA members.			

BHA should explore the use of contractors to fulfill the functions for open project positions.

In Progress

IV&V Findings & Recommendations Project Performance Metrics

Metric	Description	IV&V Observations		IV&V	Updates	
	 Review and validate the velocity data as reported by the 	as January: There were no deployments in January t is 2025.	Velocity	Metric Tre	nds:	
Velocity	projectVerify the project is		Release	Planned velocity	Actual velocity	Percentage attained
	on pace to hit the total target number of US/USP		R4.10	111		-

Release	Planned velocity	Actual velocity	Cumulative variance
R4.1	309	114	-195
R4.2	85	174	-106
R4.3	85	124	-67
Golden Record Mid-Sprint Deployment (MSD)	0	68	1
R4.4	240	225	-14
R4.5	95	76	-33
R4.6	84	103	-14
R4.7	111	50	-75
R4.8	111	107	-79
4.9	111	71	-119

Phase 4 Releases
Cumulative Variance



www.publicconsultinggroup.com

IV&V Findings & Recommendations Project Performance Metrics (cont'd.)

Metric	Description	IV&V Observations	IV&V Updates
Defect Metrics	 Understand and track the following: Defects by category (bug fixes) USPs assigned to defects in a release vs. USPs assigned to planned US in a release 	There were no deployments in January 2025.	N/A

Note*: This defect percentage does not include defects under warranty that are assigned zero (0) User Story Points.



Appendix A: IV&V Rating Scales
Appendix A IV&V Rating Scales

This appendix provides the details of each finding and recommendation identified by IV&V. Project stakeholders are encouraged to review the findings and recommendations log details as needed.

- See Findings and Recommendations Log (provided under separate cover)
- IV&V Assessment Category Rating Definitions

The assessment category is under control and the current scope can be delivered within the current schedule. The assessment category's risks and issues have been identified, and mitigation activities are effective. The overall impact of risk and issues is minimal. The assessment category is proceeding according to plan (< 30 days late). The assessment category is under control but also actively addressing resource, schedule or scope challenges that have arisen. There is a clear plan to get back on track. The assessment category's risk and/or issues have been identified, and further mitigation is required to facilitate forward (\mathbf{Y}) progress. The known impact of potential risks and known issues are likely to jeopardize the assessment category. Schedule issues are emerging (> 30 days but < 60 days late). Project leadership attention is required to ensure the assessment category is under control. The assessment category is not under control as there are serious problems with resources, schedule, or scope. A plan to get back on track is needed. The assessment category's risks and issues pose significant challenges and require immediate mitigation and/or escalation. The project's ability to complete critical tasks and/or meet the project's objectives is compromised and is R preventing the project from progressing forward. Significant schedule issues exist (> 60 days late). Milestone and task completion dates will need to be re-planned.

Executive management and/or project sponsorship attention is required to bring the assessment category under control.



Appendix A

Finding Criticality Ratings

Criticality Rating	Definition
•	A high rating is assigned if there is a possibility of substantial impact to product quality, scope, cost, or schedule. A major disruption is likely, and the consequences would be unacceptable. A different approach is required. Mitigation strategies should be evaluated and acted upon immediately.
M	A medium rating is assigned if there is a possibility of moderate impact to product quality, scope, cost, or schedule. Some disruption is likely, and a different approach may be required. Mitigation strategies should be implemented as soon as feasible.
	A low rating is assigned if there is a possibility of slight impact to product quality, scope, cost, or schedule. Minimal disruption is likely, and some oversight is most likely needed to ensure that the risk remains low. Mitigation strategies should be considered for implementation when possible.



Appendix B: Inputs



Appendix B Inputs

This appendix identifies the artifacts and activities that serve as the basis for the IV&V observations.

Meetings attended during the January 2025 reporting period:

- 1. Daily Scrum Meetings
- 2. Daily Design Meetings
- 3. Twice Weekly RSM Issues Meeting
- 4. Weekly BHA-ITS Program Status Meeting
- 5. Bi-Weekly Check-in: CAMHD
- 6. Bi-Weekly Check-in: DDD
- 7. BHA (CAMHD & DDD) IV&V Joint Meeting
- 8. IV&V Draft IV&V Status Review Meeting with DOH
- 9. DOH BHA IT Solution Project Steering Committee
- 10. US# Testing & Request Items
- 11. AER Analytics Bi-weekly Meeting
- 12. IV&V Interviews

Eclipse IV&V[®] Base Standards and Checklists



Artifacts reviewed during the January 2025 reporting period:

- 1. Daily Scrum Notes
- 2. Twice Weekly Issues Meeting Notes
- 3. Weekly BHA-ITS Program Status Report
- 4. Release 4.7 Release Notes



Appendix C: Project Trends

Appendix C Project Trends

	April	May	June	July	August	September	October	November	December	January
User Story Validation										
Test Practice Validation										
Sprint Planning										
Release / Deployment Planning										
OJT and KT Sessions										
Targeted KT										
Project Performanc e Metrics										
Organizatio nal Maturity Metrics										
General Project Manageme nt										
Resource Manageme nt										
Total Open Findings	12	13	13	12	12	14	14	14	14	14
Issue - high	0	0	0	0	0	0	0	0	0	0
Issue - medium	8	8	8	8	8	10	10	10	10	10
Issue - low	1	1	1	1	1	1	1	1	1	1
Risk - high	0	0	0	0	0	0	0	0	0	0
Risk - medium	2	2	2	2	2	2	2	2	2	2
Risk - low	0	0	0	0	0	0	0	0	0	0
Preliminary Concern	1	2	2	1	1	2	2	2	2	2



Appendix D Acronyms and Definitions

Acronyms	Definition
DOH	Department of Health
BHA	Behavioral Health Services Administration
CAMHD	Child & Adolescent Mental Health Division
FHIR	Fast Healthcare Interoperability Resources
DDI	Design Development Implementation
DDD	Developmental Disabilities Division
SI	System Integrator
USP	User Story Points
SME	Subject Matter Expert
SIT	System Integration Testing
MS	Microsoft
MSD	Mid Sprint Deployment
ADO	Azure DevOps
SLA	Service Level Agreement
RCA	Root Cause Analysis
UAT	User acceptance testing
OJT	On-the-Job Training
KT	Knowledge Transition
SFTP	Secure File Transfer Protocol
IV&V	Independent Verification and Validation
CMS	Centers for Medicare & Medicaid Services
AER	Adverse Events Report



Appendix E List of Production Defects

# ID 💌 Work Item Type	Divisi -	Title	Prior Severity	Found I	Created Date
1 30634 Bug	CAMHD	CAMHD Bug - Credentialing documents not copied into PROD during Data Migration	3 3 - Medium	PROD	2/16/2021 15:45
2 30726 Bug	DDD	Portal signature fields do not accept touchscreen input	2 3 - Medium	PROD	9/17/2021 9:07
3 33099 Bug	DDD	Bug - Duplicate IP created when cloning an ISP with an IP tied to two plan services	2 3 - Medium	PROD	2/9/2023 16:28
4 33550 Bug	CAMHD	Bug: "Progress Notes Associated to Invoices" page not loading	3 3 - Medium	PROD	3/31/2023 17:11
5 33841 Bug	DDD	Bug - Calculator 3.0 - Users able to schedule service past ISP end date again	3 3 - Medium	PROD	5/17/2023 8:22
6 34110 Bug	DDD	Bug - Individual Budget unlinking from Service Authorizations	2 3 - Medium	PROD	7/27/2023 15:40
7 34238 Bug	CAMHD	BUG - Assessment Entity Initial Save Time - IMHE	2 3 - Medium	Prod	8/17/2023 2:33
8 34242 Bug	DDD	Bug - Case Merge - Contact Notes not merging; Permissions error	2 3 - Medium	PROD	8/17/2023 8:44
9 34969 Bug	DDD	Bug - Duplicate Provider Plans	2 3 - Medium	PROD	2/23/2024 5:58
		Bug - Provider Portal AER Date/Time field for Treated by Ambulance/Emergency Medical			
10 35041 Bug	DDD	Person is hidden on viewing in Edit Mode	2 3 - Medium	Prod	3/11/2024 8:47
11 35278 Bug	DDD	Bug - Cal3.0 - BiMonthly Recurrence authorization not taking into account Unit of Service	2 3 - Medium	PROD	6/3/2024 11:53
12 35317 Bug	DDD	DDD - Plan Services with no Provider Plan	2 3 - Medium	PROD	6/24/2024 9:06
13 35450 Bug	DDD	DDD - Calculator not printing correctly	2 3 - Medium	PROD	7/26/2024 8:36
14 36383 Bug	DDD	DDD - Calculator problem with paid base and add on	2 3 - Medium	PROD	9/26/2024 9:19
15 36854 Bug	DDD	DDD - Inspire - backed up ISP in the wrong place	1 3 - Medium	PROD	10/31/2024 3:13
16 37186 Bug	Both	Both - "On deactivation of Plan Service - deactivate related Provider Plan Service Flow" issue	1 3 - Medium	PROD	12/6/2024 9:10
17 37387 Bug	DDD	DDD - C3.0 - MYC New Service Details Not Appearing	2 3 - Medium	PROD	12/16/2024 8:30
18 37388 Bug	DDD	DDD - C3.0 - Change of Provider One Time Authorizations Not Splitting Units	2 3 - Medium	PROD	12/16/2024 8:33
19 37599 Bug	DDD	DDD - Provider cannot submit an AER due to duration error	2 3 - Medium	PROD	1/15/2025 10:52
20 37663 Bug	DDD	Data Update to Account for Missing Provider Plan Value on Plan Service	1 3 - Medium	PROD	1/23/2025 8:01
21 37694 Bug	DDD	DDD - TCM batch file date is different in PROD from other environments	2 3 - Medium	PROD	1/29/2025 8:25





Solutions that Matter

	Short Description	Finding Statement	Analysis and Significance	Recommendation	Finding Update	Category	Туре	Priority	Status	Closed Date	Identified Date	Owner	
2	Regression testing	As a result of regression testing not being consistently	R3.3 introduced a defect that deprecated features in production specific to Integrated	1. To ensure effective Tosca testing, it is crucial for both divisions to align on	1/31/25 - Regression Testing for R4.10 is scheduled from 1/29/2025 to 2/5/2025. One	Test Practice	Issue	Medium	Open		12/31/2019	Gautam	
		performed, production releases are breaking existing	Support and Life Trajectory functionality. DDD has informed IV&V that there are other	a unified resource allocation strategy. Given the limited availability of	defect (view on the DDD supervisor dashboard) has come out of regression testing.	Validation						Gulvady	
		functionality in the production environment.	examples of functionality being deprecated after a release, some of which are still being	resources, open communication and consensus-building are essential for	CAMHD will conduct a mix of manual and automated testing, while DDD will focus on								
			investigated. As of this report, IV&V has not evaluated the project's root cause analysis (RCA)		manual regression testing. To support future Phase 4 releases beyond R4.10, the								
			process used to determine why such functionality was deprecated but will discuss further	share critical test cases, and identify overlapping areas, the divisions can	project plans to onboard a Tosca automated regression testing Subject Matter Expert								
			with BHA in January 2020.	achieve comprehensive regression testing without overburdening a single	(SME). The plans and timeline for Tosca automated regression testing are being								
			Thorough vetting and validation of regression test cases are necessary to prevent defects	resource. This collaborative approach will balance workloads, streamline	reviewed, with plans to commence work on 3/1/2025. For the AER project, the SI is								
			when a release is pushed live. When defects occur in production, the project should follow a		preparing to conduct regression testing on AER functionality.								
			defined and repeatable process for determining the root cause of the problem.	Ultimately, it will enable both divisions to efficiently meet their testing objectives.									
				objectives.	12/31/24 - R4.9 regression testing was conducted manually from 11/25/2024 to 12/4/2024, identifying one (1) defect. However, users encountered three (3) production								
				2. A balanced approach that combines manual and automated regression	defects in R4.9. IV&V remains concerned about the exclusive reliance on manual								
				testing to ensure broad test coverage and flexibility.	regression testing, which poses risks such as inefficiencies, human error, limited test								
				testing to ensure broad test coverage and nexibility.	coverage, and dependency on specific testers. IV&V recommends investing in								
				3. Having board(s) in Azure DevOps or a document on SharePoint that	automated regression testing to enhance efficiency, reduce the burden on BHA staff,								
				provides information about the status of regression testing automation, to	and improve product quality.								
				facilitate visibility and transparency to BHA project personnel and	For R4.10, regression testing is planned for 1/29/2025-2/5/2025, with CAMHD utilizing								
				stakeholders.	TOSCA for automated regression testing and DDD relying solely on manual testing.								
				stakeholders.	TOSCA for automated regression testing and DDD relying solely on manual testing.								
				A 11/8/V recommends regulating the schedule priorities by distributing the	11/30/2024 - For the 3rd consecutive release (releases 4.7 through 4.9), regression								
				work according to the resource bandwidth. This will ensure that the	testing is being done solely manually. Relying solely on manual regression testing								
				schedule is not impacted and that the work is done efficiently between	without any automation could introduce risks and inefficiencies such as increased time								
				regression testing and Golden Record (GR).	and effort that may lead to delays, human error, inconsistencies as testing outcomes								
				regression testing and dolden necord (dit).	can vary depending on the individual tester, limited test coverage, risk of production								
				5. Pursue and complete additional formal training in Azure DevOps and	defects since manual testing is prone to human error and the likelihood of defects								
				Tricentis for test automation as soon and complete efforts to automate the	slipping through to production increases, and the dependence on specific testers'								
				two primary regression test scripts.	expertise and knowledge.								
				two primary regression test scripts.	IV&V recommends continuing investing in automated regression testing as it can								
				6 IV/8/V recommends DDD and CAMHD to develop a common and consistent	improve efficiency and reduce the burden on BHA staff and ensure better product								
				approach across divisions for performing regression testing.	quality over time.								
				approach across annaions for performing regression resting.	quarty over time.								
				7. Determine if current regression testing timeframes are adequate and if	10/31/24 - Automated regression test script (Tosca) issues have yet to be resolved,								
				not, add more time to the pre-production regression test efforts for all	therefore, regression testing continues to be performed manually. The most recent								
14	Code quality	Due to multiple quality concerns, the project may continue	System defects identified in August that affected claims were due to multi-faceted quality	The project utilize tools such as SonarQube for continuous inspection of	1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 21 unresolved	Project Management	Issue	Medium	Open		9/30/2020	Gautam	
		to face impactful system defects.	issues were individually addressed during this reporting period. IV&V notes that there is	code quality and establishing a source code quality threshold to maintain	production defects remain, all of medium severity (refer to Appendix E for a list of				·			Gulvady	
			one remaining defect still being evaluated that affects a limited number of claims. Overall,	high-quality, secure, and maintainable code.	unresolved production defects). The SI indicated that BHA prioritizes higher-priority								
			the Project Team has responded with a commitment to increase project quality and is in the		tasks, delaying the resolution of lower-priority defects. Efforts are underway to address								
			the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently	The project increases comprehensive testing prior to joint testing to reduce	tasks, delaying the resolution of lower-priority defects. Efforts are underway to address these issues. The FHIR development was completed and deployed to production on								
				The project increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and reduce post-production defects.									
			process of identifying improvements to associated testing processes. These currently	the burden on BHA testers and reduce post-production defects.	these issues. The FHIR development was completed and deployed to production on								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are	the burden on BHA testers and reduce post-production defects.	these issues. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. IV&V will continue to								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User	the burden on BHA testers and reduce post-production defects. I The SI vendor add a "Found In" column to the daily scrum file to indicate the	these issues. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. IV&V will continue to								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10 and validate that enhanced quality processes, including industry standard regression testing, continue for Acceptance testing.	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified.	these issues. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The AER Solution golies is scheduled for 2/21/2025. IV&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke								
			process of identifying improvements to associated testing processes. These currently include: Performing Bereure Neutraling Testing to ansure expected revueu streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10 and validate continue to monitor the testing efforts throughout the balance of Release 3.10 and validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally, USAV reviewed and provided feedback on the Help Desk	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and	these issues. The FHIR development was completed and deployed to production on 1/29/25, with dealsy due to issues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. IV&V will continue to monitor the quality of both MA.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. A mid-sprint deployment with two (2) user stories								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. UKW will continue to monitor the testing efforts throughout the balance of Release 3.10. and validate that enhanced quality processes, including industry standard regression testing, continue for Aglie Release 3.11 forward. Finally, IV&V reviewed and provided feedback on the Heip Desk and Semantic Layer design documents per cequest and found that both documents lacked	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified.	these issues. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The &R4 Solution golive is scheduled for 2/21/2025. IV&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. A mid-sprint deployment with two (2) user stories followed on 12/6/2024. Currently. 19 production defects remain nuresolved (18								
			process of identifying improvements to associated testing processes. These currently include: Performing Berenue Neutrality Testing to ensure expected revenue streams rare largely unchanged from one period to the next. Conducting System Integration Testing, Lea Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.10. IV&V will dagle Release 3.11 forward. Finally, IV&V reviewed and provided Fedeback on the Help Dease and Experiments to the stating efforts throughout the provided Fedeback on the Help Dease and Semantic Layer design documents per request and found that both documents lacked design details.	the burden on BHA testers and reduce post-production defects. I The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA.	these issues. The FHIR development was completed and deployed to production on 1/29/25, with dealsy due to issues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. VI&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. A mid-sprint deployment with two (2) user stories followed on 12/6/2024. Currently, 19 production defects remain unresolved (18 medium severity. 1 high severity) despite thorough testing. The S1 stated that BHA								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.31. Olar validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally IV&V reviewed and provided feedback on the Help Deex and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. Evaluate existing project staff skills and experience level to ensure they meet	these issues. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to integrating with Microsoft and Apple Health. The &R Solution go-live is scheduled for 2/21/2025. IV&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/5/2024. A mic-sprint deployment with two c2) user stories followed on 12/16/2024. Currently, 19 production defects remain unresolved (18 medium severity, 1 high severity) despite thorough testing. The S1 stated that BHA prioritizes higher-priority tasks, leaving lower-priority defects unadresed. The S1 is								
			process of identifying improvements to associated testing processes. These currently include: Performing Berenue Neutrality Testing to ensure expected revenue streams rare largely unchanged from one period to the next. Conducting System Integration Testing, Lea Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.10. IV&V will dagle Release 3.11 forward. Finally, IV&V reviewed and provided Fedeback on the Help Dease and Experiments to the stating efforts throughout the provided Fedeback on the Help Dease and Semantic Layer design documents per request and found that both documents lacked design details.	the burden on BHA testers and reduce post-production defects. I The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA.	these issues. The FHIR development was completed and deployed to production on 1/29/25, with deals due to sissue related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. VI&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. A mid-aprint deployment with two (2) user stories followed on 12/16/2024. Currently, 19 production defects remain unresolved (18 medium severity, 1 high severity) despite thorough testing. The S1 stated that BHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The S1 is working to resolve these issues. (V8W and BHA remain concerned about nogning code								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.31. Olar validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally IV&V reviewed and provided feedback on the Help Deex and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	the burden on BHA testers and reduce post-production defects. The SI wendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements.	these issues. The FHIR development was completed and deployed to production on 1/29/25, with dealsy due to sissue related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. IV&V will continue to monitor the quality of both RA-10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4-9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/5/2024. A mid-sprint deployment with two (2) user stories followed on 12/fo/2024. Currently, 19 production defects remain unresolved (18 medium severity, 1 high severity) despite thorough testing. The SI stated that BHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The SI is working to resolve these issues, IV&V and BHA remain concerned about ongoing code quality problems and their impact on users. BHA is considering utilitize tools such as								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.31. Olar validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally IV&V reviewed and provided feedback on the Help Deex and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. Perform CAMHD revenue neutrality fiscal balance testing on a quarterly	these issues. The FHIR development was completed and deployed to production on 1/29/25, with deals due to sissue related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. VI&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. A mid-aprint deployment with two (2) user stories followed on 12/16/2024. Currently, 19 production defects remain unresolved (18 medium severity, 1 high severity) despite thorough testing. The S1 stated that BHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The S1 is working to resolve these issues. (V8W and BHA remain concerned about nogning code								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.31. Olar validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally IV&V reviewed and provided feedback on the Help Deex and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	the burden on BHA testers and reduce post-production defects. The SI wendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements.	these issues. The FHIR development was completed and deployed to production on 1/29/25, with deals due to sissue related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. IV&V will continue to monitor the quality of both RA.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/5/2024. A mid-spirit deployment with two (2) user stories followed on 12/16/2024. Currently, 19 production defects remain unresolved (18 medium sverity). Thigh sverity/16 solpite thorough testing. The S1 stated that EHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The S1 is working to resolve these issues, IV&V and BHA remain concerned about ongoing code quality problems and their impact on users. BHA is considering utilizing tools such as SonarQube for continuous inspection and improvement of code quality.								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.31. Olar validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally IV&V reviewed and provided feedback on the Help Deex and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. Perform CAMHD revenue neutrality fiscal balance testing on a quarterly	these issues. The FHIR development was completed and deployed to production on 1/29/25, with dealsy due to sissues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. VI&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/37- R4.94 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. A mid-sprint deployment with two (2) user stories followed on 12/16/2024. Currently, 19 production defects remain unresolved (18 medium severity. Thigh severity) despite thorough testing. The Si tated that BHA prioritizes higher-priority tasis, leaving lower-priority defects unaddressed. The Si is working to resolve these issues. (VAV and BHA rement or concered about negoing code quality problems and their impact on users. BHA is considering utilizing tool such as SonarQueb for continuous inspection and improvement of code quality. 11/30/2024 - R4.9 is scheduled to be deployed to production on 12/5/2024. In the								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.31. Olar validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally IV&V reviewed and provided feedback on the Help Deex and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. Perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected.	these issues. The FHIR development was completed and deployed to production on 1/29/25, with dealsy due to issues related to integrating with Microsoft and Apple Health. The AER solution go-line is scheduled for 2/21/2025. IV&V will continue to monitor the quality of both RA.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/5/2024. A mid-sprint deployment with two (2) user stories followed on 12/16/2024. Currently, 19 production defects remain unresolved (18 medium severity, 1 high severity) despite thorough testing. The S1 stated that EHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The S1 is working to resolve these issues. (19 WA und BHA remain concerned about negoing code quality problems and their impact on users. BHA is considering utilizing tools such as SonarQuebe for continuous inspection and improvement of code quality. 11/30/2024 - R4.9 is scheduled to be deployed to production on 12/5/2024. In the current production system, three exists 19 outstanding production defects (17 are								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.31. Olar validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally IV&V reviewed and provided feedback on the Help Deex and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. Perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected.	these issues. The FHIR development was completed and deployed to production on 1/29/25, with dealsy due to sissues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. VI&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 1/23/12/4. R4. Ye was deployed to production on 1/25/2024, with successful smoke testing completed on 12/16/2024. A mid-spinit deployment with two (2) user stories. followed on 12/16/2024. Currently, 19 production defects runal unresolved (18 medium severity, 11 high severity) despite thorough testing. The SI stated that BHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The SI is working to resolve these suser, IVAV and BHA rement of code quality. 11/30/2024 - R4.9 is scheduled to be deployed to production on 12/5/2024. In the current production system, there exists 19 outstanding production defects 17 are classified as medium severity and 2 a high severity). These production defects (17 are classified as medium severity and 2 a high severity).								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.31. Olar validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally IV&V reviewed and provided feedback on the Help Deex and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. Perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes.	these issues. The FHIR development was completed and deployed to production on 12925s, with dealsy due to issues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. VI&V will continue to monitor the quality of both RA.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. A mid-sprint deployment with two (2) user stories followed on 12/16/2024. Currently, 19 production defects remain unresolved (18 medium severity). Thigh severity) despite thorough testing. The S1 stated that EHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The S1 is working to resolve these issues. (V&W and BHA remain concerned about nogning code quality problems and their impact on users. BHA is considering utilizing tools such as SonarQube for continuous inspection and improvement of code quality. 13/30/2024 - R4.9 is scheduled to be deployed to production on 12/5/2024. In the current production system, there exists 19 outstanding production defects 17 are classified as medium severity and 2 as high severity). These production defects areas despite testing at all levels. The S1 has indicated that BHA proritizes to work, which								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.31. Olar validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.11 forward. Finally IV&V reviewed and provided feedback on the Help Deex and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. Perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected.	these issues. The FHIR development was completed and deployed to production on 1/29/25, with dealsy due to sissue related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. IV&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 1/23/12/4. R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/16/2024. A mid-sprint deployment with two [2] was risories. followed on 12/16/2024. Currently, 19 production defects remain unresolved (18 medium severity, 1 high severity) despite thorough testing. The SI stated that BHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The SI is working to resolve these suses, IV/8V and BHA rement of code quality. 11/30/2024 - R4.9 is scheduled to be deployed to production on 12/5/2024. In the current production system, there exists 19 outstanding production defects (17 are classified as medium severity, and 2 high severity). These production defects for and elsopties that all levels. The SI has indicated that BHA BHA prioritizes its work, which results in lower-priority defects treaming unresolved in favor of higher-priority tasks.								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.10. and validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.10 mark validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.10 mark validate and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. Perform CAMHD revenue neutrality fiscal balance testing on a quarterfy basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness.	these issues. The FHIR development was completed and deployed to production on 1/29/25, with dealsy due to issues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. VI&V will continue to monitor the quality of both RA.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. A mid-sprint deployment with two (2) user stories followed on 12/6/2024. Currently, 19 production defects remain unresolved (18 medium severity). Thigh severity) despite thorough testing. The S1 stated that EHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The S1 is working to resolve these issues. (V&W and BHA remain concerned about negoing code quality problems and their impact on users. BHA is considering utilizing tools such as SonarQube for continuous inspection and improvement of code quality. 11/30/2024 - R4.9 is scheduled to be deployed to production on 12/5/2024. In the classified as medium severity and 2 as high severity). These production defects areas despite testing at levels. The S1 has indicated that BHA prointizes to work, which results in lower-priority defects remaining unresolved in favor of higher-priority tasks. The S1 is making a concerted efforts to report and fix these production defects as IVB.								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.10. and validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.10 mark validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.10 mark validate and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. Perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM after all	these issues. The FHIR development was completed and deployed to production on 1/29/25, with dealsy due to sissue related to integrating with Microsoft and Apple Health. The AER solution golive is scheduled for 2/21/2025. VRV will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 1/21/1/24 - R4.9 was deployed to production on 1/2/5/2024, with successful smoke testing completed on 12/6/2024. A mid-sprint deployment with two (2) user stories followed on 12/6/2024. Currently, 39 production defects remain unresolved (18 modum severity, 1 high severity) despite thorough testing. The SI stated that BHA prioritizes higher-priority task, leaving lower-priority defects unaddressed. The SI is working to resolute these issues (VW and BHA remme I or concerned about congoing odde quality problems and their impact on users. BHA is considering utilizing tools such as SonarQueb for continuous inspection and improvement of code quality. 11/30/2024 - R4.9 is scheduled to be deployed to production on 12/5/2024. In the current production system, there exists 19 outstanding production defects tars with which results in lower-priority defects thas indicated that BHA prioritizes its work, which results in lower-priority defects compliant defects as V&V and BHA remains concerned that to de quality issues continue to impact the project, and a blag a concerted effort to report and fix these production defects as V&V and BHA remains concerned that code quality issues continue to impact the project, and BHA remains concerned that code quality issues continue to impact the project, and BHA remains concerned that code quality issues continue to impact the project, and BHA remains concerned that code quality issues continue to impact the project, and BHA remains concerned that code quality issues continue to impact and bHA remains with and BHA remains the project, and BHA remains the project, and bHA remains with and BHA remains the project and bHA remains with project. Ama Ama Ama B								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.10. and validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.10 mark validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.10 mark validate and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. Perform CAMHD revenue neutrality fiscal balance testing on a quarterfy basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness.	these issues. The FHIR development was completed and deployed to production on 1/29/25, with dealsy due to issues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. VI&V will continue to monitor the quality of both RA.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. A mid-sprint deployment with two (2) user stories followed on 12/6/2024. Currently, 19 production defects remain unresolved (18 medium severity). Thigh severity) despite thorough testing. The S1 stated that EHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The S1 is working to resolve these issues. (V&W and BHA remain concerned about negoing code quality problems and their impact on users. BHA is considering utilizing tools such as SonarQube for continuous inspection and improvement of code quality. 11/30/2024 - R4.9 is scheduled to be deployed to production on 12/5/2024. In the classified as medium severity and 2 as high severity). These production defects areas despite testing at levels. The S1 has indicated that BHA prointizes to work, which results in lower-priority defects remaining unresolved in favor of higher-priority tasks. The S1 is making a concerted efforts to report and fix these production defects as IVB.								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.10. and validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.10 mark validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.10 mark validate and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. Perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality improvement.	these issues. The FHIR development was completed and deployed to production on 1/29/25, with dealsy due to sissue related to integrating with Microsoft and Apple Health. The AER solution golive is scheduled for 2/21/2025. VRV will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 1/21/12/- R4.9 was deployed to production on 1/2/5/2024, with successful smoke testing completed on 12/6/2024. A mid-sprint deployment with two (2) user stories followed on 12/6/2024. Currently, 3 production defects remain unresolved (18 medium severity, 1 high severity) despite thorough testing. The SI stated that BHA prioritizes higher-priority task, leaving lower-priority defects unaddressed. The SI is working to resolve these issues: (VW and BHA remune of code quality. 11/30/2024 - R4.9 is scheduled to be deployed to production on 12/5/2024. In the current production system, there exists 19 outstanding production defects is work, which results in lower-priority das high saverity. These production defects is working to resolution servert and a 2 high saverity). These production defects is NWA with results in lower-priority defects to a big fixed in favor of higher-priority tasks. The SI has indicated that BHA profittes its work, which results in lower-priority defects remaining unresolved in favor of higher-priority defects and and BHA remains concerred effort to report and fix these production defects as V&V and BHA remains concerned that code quality issues continue to impact the project, and users continue to be impacted by post-production bugs.								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.10. and validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.10 mark validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.10 mark validate and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. Perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for ortinual quality improvement. BHA and RSM to collaborate on the necessary revisions to the submitted	these issues. The FHIR development was completed and deployed to production on 1/29/25, with dealsy due to issues related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. VI&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. A mid-aprint deployment with two (2) user stories tasting completed on 12/6/2024. A mid-aprint deployment with two (2) user stories followed on 12/6/2024. Currently, 19 production defects remain unresolved (18 medium severity). Thigh severity/04 Sepite thorough testing. The S1 stated that BHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The S1 is working to resolve these issues. (VWA and BHA remain concered about nogning code quality problems and their impact on users. BHA is considering utilizing tools such as SonarQube for continuous inspection and improvement of code quality. 11/30/2024. At 9 is scheduled to be deployed to production on fefcets ar08.27 are classfied as medium serverity and 2 a high serverity. These production defects ar08.27 and a schedulers are also and a law inspection in these production defects ar08.27 and elsafield as media concerted efforts to report and in these production defects ar08.27 and the S1 is making a concerted efforts to report and in these production defects ar08.27 and HA remain concerned that code quality issues continue to impact the project, and users continue to be impacted by post-production bugs. 10/31/24 - The deployment of R4.8 to production occurred on October 16, 2024, which								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.10. and validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.10 mark validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.10 mark validate and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. Perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality improvement.	these issues. The FHIR development was completed and deployed to production on 1/29/55, with dealsy due to sissue related to integrating with Microsoft and Apple Health. The AER solution golive is scheduled for 2/21/2025. VI&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 1/2/11/24 - R4 9 was deployed to production on 1/2/5/024, with successful smoke testing completed on 12/5/0204. A mid-sprint deployment with two (2) user stories followed on 12/6/2024. Currently, 19 production defects remain unresolved (18 medium severity). 1 high severitry despite thorough testing. The S1 stated that BHA prioritizes higher-priority task, leaving lower-priority defects unadiancessd. The S1 sona/Qub for continuous inspection and improvement of code quality. 11/30/2024 - R4.9 is scheduled to be deployed to production on 12/5/2024. In the current production system, there exists 19 outstanding production defects 12 are dasafied as medium severitry al a high severity. These production defects 12 are dasafied as medium severitry and a high severitry and a high severity and an high very medi- results in lower-priority dasks. Leaving and the HA production defects 12 are dasafied as medium severitry and a high severitry and as high severitry and an high very media in favor of higher-priority defacts unadiated. The S1 is making a concerted effort to report and fix these production defects at N&V and BHA remains concerred that to production burges. 10/31/24 - The deployment of R4.8 to production occurred on October 16, 2024, which was later than the originally planned date of October 3, 2024. This timeline shift was a the site in lower single planned date of October 3, 2024, which was later than the originally planned date of October 3, 2024. This timeline shift was the site in lower originally planned date of October 3, 2024. This timeline shift was the site find the originally planned date of October 3, 2024. This timeline shift was the original to planned date of Octobe								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.10. and validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.10 mark validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.10 mark validate and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. Perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality improvement. BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality.	these issues. The FHIR development was completed and deployed to production on 1/29/25, with deals due to sissue related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. VI&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. A mid-aprint deployment with two (2) user stories tasting completed on 12/6/2024. A mid-aprint deployment with two (2) user stories followed on 12/6/2024. Currently, 19 production defects remain unresolved (18 medium severity, 11 bigh severity) despite thorough testing. The S1 stated that BHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The S1 is working to resolve these issues. (VW and BHA remain concerned about nogoing code quality problems and their impact on users. BHA is considering utilizing tools such as SonarQube for continuous inspection and improvement of code quality. 11/30/2024. At 9.9 is scheduled to be deployed to production on fefects 10/27 are classified as medium servity and 2 a high servity). These production defects as IV&V and BHA remain concerned birts to report and fix these production defects as IV&V and BHA remain concerned that code quality issues continue to impact the project, and user, continue to be impacted by post-production bugs. 10/31/24 - The deployment of R4.8 to production occurred on October 16, 2024, which was later than the originally planned date of October 3, 2024. This timeline shift was influenced by a Microsoft fix connex test os parts with Services 10/31/24 - The deployment of R4.8 to production scurred on October 16, 2024, which was later than the originally planned date of October 3, 2024. This timeline shift was influenced by a Microsoft fix connex test os approximates behavioral Health Services 10/31/24 - The deployment of R4.8 to production scurred on October 16, 2024, which was later								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.10. and validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.10 mark validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.10 mark validate and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. Perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for including yrevisions to the submitted design deliverables to increase level of detail and quality. Perform typical project testing including System Integration, User	these issues. The FHIR development was completed and deployed to production on 1/29/55, with dealsy due to sissue related to integrating with Microsoft and Apple Health. The AER solution golive is scheduled for 2/21/2025. VI&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 1/2/11/24 - R4.9 was deployed to production on 1/2/5/024, with successful smoke testing completed on 12/5/0204. A mid-sprint deployment with two (2) user stories followed on 12/6/2024. Currently. B production defects remain unresolved (18 medium severity). 1 high severityl despite thorough testing. The S1 stated that BHA prioritizes higher-priority task, leaving lower-priority defects unadiancessd. The S1 sona/Qub for continuous inspection and improvement of code quality. 11/30/2024 - R4.9 is scheduled to be deployed to production on 12/5/2024. In the current production system, there exists 19 outstanding production defects 1/2 are daspite testing at all levels. The S1 has indicated that BHA prioritizes its work, which results in lower-priority dask, leaved in flavor of higher-priority tasks. The S1 is making a concerted effort to report and fix these production defects at 10/8/ and BHA remain concerred that to de quality lisses confluent to impact the project, and users continue to be impacted by post-production bugs. 10/31/24 - The deployment of R4.8 to production october 16, 2024, which was later than the originally planed date of October 3, 2024. This timeline shift was influenced by a Microsoft fix connected to a previous Behavioral Health Services Administration (BHA) ticket. This fix introduced critical issues in the Provider Poral densite testing at Health development of R4.8 to previous Behavioral Health Services Administration (BHA) ticket. This fix introduced critical issues in the Provider Poral deministration (BHA) ticket. This fix introduced critical issues in the Provider Poral deministration (BHA) ticket. This fix introduced critical issues in the Provider Poral								
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, Use Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.10. and validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.10 mark validate that enhanced quality processes, including industry standard regression testing, continue for Agile Release 3.10 mark validate and Semantic Layer design documents per request and found that both documents lacked design details. The identified quality issues have negatively affected DOH billing processes and DOH has	the burden on BHA testers and reduce post-production defects. The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was identified. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. Perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. Monitor implemented improvements for effectiveness. IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality improvement. BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality.	these issues. The FHIR development was completed and deployed to production on 1/29/25, with deals due to sissue related to integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for 2/21/2025. VI&V will continue to monitor the quality of both R4.10, FHIR, any MSDs, and the AER solution. 12/31/24 - R4.9 was deployed to production on 12/5/2024, with successful smoke testing completed on 12/6/2024. A mid-aprint deployment with two (2) user stories tasting completed on 12/6/2024. A mid-aprint deployment with two (2) user stories followed on 12/6/2024. Currently, 19 production defects remain unresolved (18 medium severity, 11 bigh severity) despite thorough testing. The S1 stated that BHA prioritizes higher-priority tasks, leaving lower-priority defects unaddressed. The S1 is working to resolve these issues. (VW and BHA remain concerned about nogoing code quality problems and their impact on users. BHA is considering utilizing tools such as SonarQube for continuous inspection and improvement of code quality. 11/30/2024. At 9.9 is scheduled to be deployed to production on fefects 10/27 are classified as medium servity and 2 a high servity). These production defects as IV&V and BHA remain concerned birts to report and fix these production defects as IV&V and BHA remain concerned that code quality issues continue to impact the project, and user, continue to be impacted by post-production bugs. 10/31/24 - The deployment of R4.8 to production occurred on October 16, 2024, which was later than the originally planned date of October 3, 2024. This timeline shift was influenced by a Microsoft fix connex test os parts with Services 10/31/24 - The deployment of R4.8 to production scurred on October 16, 2024, which was later than the originally planned date of October 3, 2024. This timeline shift was influenced by a Microsoft fix connex test os approximates behavioral Health Services 10/31/24 - The deployment of R4.8 to production scurred on October 16, 2024, which was later								

ID Short Description	Finding Statement	Analysis and Significance	Recommendation	Finding Update	Category	Туре	Priority	Status	Closed Date	Identified Date	e Owner	
31 Sprint Demos	Lack of regular Sprint Reviews and Sprint Demos will likely lead to misalignments between delivered work and stakeholder needs.	Earlier in the project, end of sprint demox were conducted. Sprint review/demox help to bring alignment across the team and stakeholders. They are essential building blocks for better software and teams. Sprint demox reviews howcase the main functionality to stakeholders and incorporate their feedback. Currently, the project has joint testing involving the 31 and BHA personnel. Per Agile Best practices, IVAX believes having Sprint demox/reviews during a sprint helps clarify and validate design prior to testing, steer the team in the right direction, and help to avoid big mistakes. This would also allow the testing team in the signification, and help to avoid big mistakes. This would also allow the testing team is the right direction, and help to avoid big mistakes. This would also allow the testing team to focus solely on testing, which is beneficial. Based on Agile Best Practices, Sprint Demos or reviews occur during a sprint with the development team, scrum matter, and product Owner and and gives all relevant stakeholders the opportunity to assess the completion of user stories, review important metrics and outcomes, and confirm if the Sprint goal has been achieved. This approach would also help prioritize and prepare the backlog for the next Sprint. Regular Sprint Reviews and demos strengthen the collaboration between development teams and stakeholders by enhancing communication channels and validating project objectives and evening that sprint deliverables remain consistent with stakeholder requirements. They are a great opportunity for the product owner, stakeholders, and the team to review what's being delivered and receive feedback. This way, the team can gauge responses and make observations earlier during development and not later during testing. Celebrating the team's accomplishments is also an essential part of these demos. Moreover, they are invaluable in steering the team in the right direction and avoiding big mistakes. It 's interesting to note that the Sprint Demox ould b	the completed work to stakeholders and gather feedback. Use this feedback to refine and reprioritize the product backlog. For a 2-month sprint, IV&V recommends having more than one (1) demo during the sprint. 2. Create a stakeholder register to identify all stakeholders. Ust their identification, assessment, and classification. Review the register regularly to plan appropriate stakeholder engagement. 3. Foster active participation from users and takeholders during both Sprint Reviews and Sprint Demos. Emphasize the value of iterative feedback to guide development and ensure that user needs are consistently met. 4. Establish standardized communication protocols for both Sprint Reviews and Sprint Demos. Encourage teams to deliver concise and informative endorse stakeholder engagement and project transparency. 5. Institute a structured documentation process for both activities. Document key decisions, action item, and insights from each sesion to ensure accountability and to support ongoing process improvement.	1/31/25 - The Sprint Review and Demos are currently being conducted ad hoc. In recent discussions, the project team has proposed incorporating both the Calculator functionality and the 'copy forward' functionality into the process. The 31 demonstrated AER Analytics functionality in December 2024, and the demos have beer valuable for DDD in validating requirements and expectations, Although DDD has worked through the requirements, some IASPIEG discrepancies have emerged during opportunity to address these discrepancies, Jaign expectations, and refine the approad as they move forward. The project team is actively exploring how to integrate these new functionalities into the reviews and demos to ensure a smooth and efficient process. 12/31/24 - IV&V was informed that sprint reviews and demos are currently conducted on an ad hoc basis. To improve the process, the project is planning to incorporate the demonstration of Calculator functionality into sprint reviews and demos. This would provide valuable visibility into the progress and help address ongoing issues with the calculator and provider portal, which are identified as frequent problem areas. 11/30/24 - The project has indicated that sprint reviews and demos are conducted on an ad hoc basis. To improve the progress and help address ongoing issues with the calculator and provider portal, which are identified as frequent problem areas. 11/30/24 - The project has indicated that sprint reviews and demos are conducted on an ad hoc basis. To improve the progress may result in inconsistent feedhask collection and depending on the completion of features. There are no regular meetings scheduled for sprint reviews. Demos are typically performed informally, ofter through quick conversitories or screen sharing, based on the priority and readiness of the features. This informal approach to demos may result in inconsistent feedhask collection and depend issue identification, which can negatively impact the overall effectiveness of the sprint. IV&V r		Risk	Medium	Open		7/26/2023	Gautam Gulvady	
33 System performance	Performance bottlenecks with the INSPIRE production environment may result in low productivity and poor user experience.	Performance issues have been identified that have the potential to impact the system's functionality, user experience, and the overall reliability of the system. These performance issues warrant immediate attention and resolution. The last performance test was executed in June 2023 for Phase 3 releases (R3.4). "300+ new User Story Points (USPs) have been developed since the last performance test execution. Developmental Joshilty Division (DDD) personnal are encountering performance issues with re-assigning cases and opening the DDD – Contact Notes (Fiscal View – Complete) view. CAMHD has not reported performance issues.	and scenarios that include both DDD and CAMHD functionality, transactions/functionality that are performance intensive, e.g., calculator functionality	misalignment between requirements and system design. IV&V continues to recommend setting up a consistent calence for Spirit Netwes and denois to validate 1/31/25 - Microsoft completed the DDD performance test and submitted its report, showing similar results between MAA and INSPIRE. IV&V has received and reviewed the performance test report. However, the Provider Portal's performance declined as user volume increased to 500. IV&V recommends conducting performance testing at least annually to ensure system stability. 12/31/24 - Microsoft conducted performance testing for CAMHD functionality (MAX and Provider Portal) with 100, 200, and 300 users and delivered the performance report. According to the report, response times for MAX and INSPIRE remained consistent during each test. However, volumes at 300 portal users exceeded 27. the consistent during each test, However, volumes at 300 portal users exceeded 27. the consistent during each test, However, volumes at 300 portal users exceeded 27. the strained response times once user volume stored 300 portal users acceeded 27. the strained for the production mode. Additionally, Microsoft is performing performance testing after the R-3 deployment once the portal environment is switched to production mode. Additionally, Microsoft is performing 1205. IVAV recomment of Ad 100 pard (AMHE). Mas completed performance testing the CAMHD performance test earlier, the project decided to execute the test from the Expriment of R-40 to porduction. The estimated timeline for completion is 1-2 weeks. 10/31/24 - Microsoft is continuing performance testing for the application and will provide the results/report upon completion. After discussions with a project stakeholder, it is agreed that when Microsoft provides the report, this report will be provided to the project testing was originally conducted from June 4 to June 12, 2024. 9/30/24 - Performance testing was originally conducted from June 4 to June 12, 2024. However, the Developmental Disabilities Divisio		Issue	Medium	Open		8/18/2023	Gsutam Gulvady	

ID	Short Description	Finding Statement	Analysis and Significance	Recommendation	Finding Update	Category	Туре	Priority	Status	Closed Date	Identified Date	Owner	
4	Limited BHA resources	Shortage of Behavioral Health Administration (BHA) project	Key BHA project resources have reported constraints on how much time they can devote to	1. Utilizing peer-to-peer knowledge sharing, allowing experienced team	1/31/25 - IV&V was informed that some cross-training had been conducted, but	Resource	Issue	Medium	Open		8/18/2023	Michael Fors	
	Linited biol resources	resources could lead to reduced productivity and project	the project. The departure of the Child and Adolescent Mental Health Division (CAMHD)	members to informally share their expertise during team meetings.	concerns remain regarding the insufficient knowledge transfer for critical tasks. While a	Management	13300	Wiedium	open		0/10/2023	Whender Fors	
		delays	System Management Office Manager and CAMHD Inspire Project Lead could further impact	Additionally, creating internal documentation that outlines best practices	limited amount of knowledge transfer occurred concerning the provider portal, it was	Management							
			the project if DOH cannot acquire suitable resources. The lack of capacity of the DOH test	and processes for developing security policies would serve as a self-service	highlighted that more comprehensive cross-training is needed, particularly for the								
			script developer has slowed DOH's automated test script development.	resource for the team.	provider and customer portals. This would help reduce the risks associated with								
			If BHA is unable to fully staff the project and their existing resources continue to be		knowledge gaps and ensure continuity in operations, especially in the event of key								
			constrained, the project could experience a reduction in productivity and project delays.	2. DDD and CAMHD have further discussions to optimize resource utilization									
				between the two divisions.	Subject Matter Expert (SME) to address the resourcing issue and improve cross-								
					training. The plans and timeline for Tosca automated regression testing are being								
				3. BHA should explore options for offloading project team members' daily	reviewed, with plans to commence work on 3/1/2025.								
				responsibilities to other staff.									
					12/31/24 - IV&V is concerned that limited resources at BHA could cause project delays								
				4. BHA should work quickly to create new positions and receive State	and affect system quality. For instance, IT staff and other departments have struggled								
				approval.	to find time to update and create security policies, as these tasks have not been								
					prioritized alongside their regular duties. BHA submitted requests for new positions,								
				5. BHA should identify tasks and duties that they can ask the SI to assume, as	which the State did not approve. The hope is that filling a key position will help address								
				permitted by the contract, which are presently being handled by BHA	this issue, allowing the new hire to take on policy drafting or free up others to focus on								
				members.	these critical tasks. While there are resources for specific tasks, only a few people have								
					the necessary skills. Expanding this knowledge and responsibility across the team is a								
				6. BHA should explore the use of contractors to fulfill the functions for open	key part of their plan.			1					
				project positions.				1			1		
					11/30/24 - IV&V remains concerned that limited BHA resources could create project			1			1		
					delays and reduce system quality. BHA requested funding for additional project			1					
					resources, however the request was not approved by the State. BHA plans to resubmit								
					the request in next year's budget and will continue to look for other resource and								
					funding options. IV&V continues to recommend that the project streamline								
					communications between BHA divisions in order to increase the productivity of project								
					activities and decision-making.								
					-								
					10/31/24 - IV&V remains concerned that inadequate DOH resources may result in								
					project delays and diminished system quality. IV&V is continuing to recommend that								
					the two divisions communicate directly to address their resourcing needs and								
					optimize resourcing. DDD plans to engage new hires in additional project areas,								
	Deployment process.	Due to on-going deployment processes and technical	Several post-production bugs have been encountered in the Phase 4 release, R4.4.	1. The Project should consider automating deployments for resource	1/31/25 - : R4.9 encountered deployment issues, prompting the creation of a defect in	Release/Deployment	Issue	Low	Open		1/25/2024	Gautam	
		execution issues, the Project may continue to encounter	Regarding the bug, "Human Services Research Institute (HSRI) flow is failing in production"	savings, increased efficiency, consistency, faster time to market, improved	ADO. BHA is actively working to resolve these issues involving missing web resources	Planning			·			Gulvady	
		defects and challenges, e.g., when releases are in production		collaboration and reliability, scalability, version control integration, and	and workflows. The R4.10 go-live is scheduled for 2/6/2025. The FHIR development was								
			https://dev.azure.com/DOHBHA/DOH%20BHA%20INSPIRE/_workitems/edit/34886), what is		completed and deployed to production on 1/29/25, with delays due to issues related to								
			in development and deployed is vastly different from what was deployed to production.		integrating with Microsoft and Apple Health. The AER solution go-live is scheduled for								
				2. Ensure there are adequate and gualified resources to support the current	2/21/2025. IV&V will continue to monitor the deployment quality of R4.10, FHIR, any								
			The root cause for these errors is currently being investigated.	deployment processes. This may require the support from RSM resources to	MSDs, and the AER solution.								
				provide assistance and knowledge transfer for some of the more complex									
			Repeatable documented release and deployment and resources experienced with	deployment components.	12/31/24 - The Root Cause Analysis (RCA) for the medium-severity defect (addressed								
			deployments will help ensure that mistakes are minimized and that functionality is not		with a hotfix deployed on 10/24/2024) identified it as deployment-related (related to								
			mistakenly deprecated when deployments take place.	3. As appropriate, consult with RSM on best practices that BHA could employ									
			······································	to support deployment.	by a mid-sprint deployment (MSD) with two user stories on 12/16/2024. IV&V will								
				to support deproyment.	monitor the quality of both the R4.9 deployment and the MSD.								
				4. Request the assistance of the RSM Solution Architect in reviewing and									
				correcting issues associated with the consistency of configurations across	11/30/2024 - The Root Cause Analysis (RCA) for the medium severity defect (for which a			1					
				environments, ensuring that the test environment is capable of testing ALL	hot fix was deployed on 10/24/24) is still pending. There were no deployments in	1		1			1		
				functions of any given release without the need for using multiple test	November 2024; R4.9 is scheduled to be deployed in December 2024. IV&V will			1					
				environments.	monitor the quality of the upcoming R4.9 deployment and MSDs.			1			1		
					montor are quarty of the upcoming two deployment and wood.			1			1		
				5. Request the assistance of the RSM Solution Architect in review of	10/31/24 - R4.8 was deployed to production on 10/16/24, instead of 10/3/24. This			1			1		
					delay was caused by a Microsoft (MS) fix related to a previously raised Behavioral			1			1		
					Health Services Administration (BHA) ticket, which introduced critical issues in the			1			1		
				commencing deployment activities.	Health services Administration (BHA) ticket, which introduced critical issues in the Provider Portal in the System Integration Testing (SIT) and Test 2 environments, halting			1			1		
				6. The Project Team should consider evaluating potential changes to	Provider Portal in the System Integration Testing (SIT) and Test 2 environments, halting testing. The SI vendor's initiative to involve the team in a root cause analysis of the			1			1		
								1			1		
				improve/enhance existing processes and communications to address current				1					
				release/deployment shortfalls.	improve understanding, alignment, and resolution strategies, contributing to the			1			1		
					project's success. The SI vendor deployed a hot fix for medium severity defect on			1			1		
				7. IV&V recommends performing an RCA in collaboration with RSM for the	10/24/24; the Root Cause Analysis (RCA) for this defect is still pending. The project			1			1		
				continued concerns surrounding environment differences.	plans to deploy Fast Healthcare Interoperability Resources (FHIR) as a mid-sprint	1	1	1			1		
				-									
					deployment (MSD). IV&V is concerned about inconsistencies in the deployment								
				8. IV&V recommends updating the Project's Configuration Management Plan	processes, particularly due to the absence of a designated deployment lead. IV&V will								

ID S	hort Description	Finding Statement	Analysis and Significance	Recommendation	Finding Update	Category	Туре	Priority	Status	Closed Date	dentified Date	Owner
) II	sufficient testing	Insufficient testing processes can lead to poor-quality	There is a limited understanding of the testing processes and the roles and responsibilities of		1/31/25 - IV&V has been requesting a walkthrough of the INSPIRE testing process since		Issue	Medium	Open		1/31/2024	Gautam
		software, project delays and extended user acceptance			10/2024, which the SI has not delivered. IV&V will continue discussions with BHA to	Validation						Gulvady
		testing.		traceability, considering new development of Access Rules, Document	ensure progress is made in advancing the SI's INSPIRE testing efforts. To support future							
			approval from state staff. When testing user stories 34564 and 34756 on 1/31/24, the test tasks did not reflect the real	management/digitization.	Phase 4 releases beyond R4.10, the project plans to onboard a Tosca automated regression testing Subject Matter Expert (SME). The plans and timeline for Tosca							
			use cases to give stakeholders adequate confidence that the user story could be tested. As a		automated regression testing are being reviewed with plans to commence work on							
			result, time was expended by testing resources, testing was inadequate, and a user story	stakeholders, ensuring their needs are met and risks are managed through	3/1/2025. UAT for AER functionality is complete, with the SI addressing defects							
			may have been deemed to meet functionality when it did not.	effective communication. A RACI clarifies roles and responsibilities,	identified during testing. Some AER testing deliverables, for example, test results,							
			,	improving collaboration, decision-making, and resource management, which								
				are all critical for the success of IT projects.								
					12/31/24 - IV&V provided a list of testing topics for the SI to address during the current							
					DD&I phase of the project. However, the SI's response focused on the M&O phase							
				matrix for testing.	rather than DD&I and did not reference updated documentation. BHA has							
					communicated to the SI that the project have always been in DD&I and the project can							
				Review the overall testing process and implement any needed	only transition to the Maintenance and Operations (M&O) phase after CMS has							
				improvements identified.	certified INSPIRE/MAX. In addition to updated documentation, IV&V continues to							
					request a walkthrough meeting to further understand the testing process. IV&V will							
					continue discussions with BHA to ensure progress is made in advancing the SI's testing efforts.							
							1	1				
					11/30/2024 - IV&V has identified specific testing areas to discuss with the appropriate		1	1				
					project representatives to gain a deeper understanding of the INSPIRE testing process.		1	1				
					DDD has agreed to facilitate the organization of these meetings.		1	1				
					10/31/24 - IV&V has requested a session to review test processes and will provide a list							
					of suggested items to cover (for example, tracking test coverage and requirements							
					traceability). The goal of this session is to identify opportunities to improve the testing							
					process, as well as the reporting of test results and coverage.							
					9/30/24 - BHA and IV&V reviewed the RACI matrix, with IV&V providing feedback. BHA							
					continues to refine and develop the RACI matrix, with twee providing reedulate. Bits							
					the right stakeholders for successful project outcomes. The SI vendor currently tracks							
					test coverage manually using Excel worksheets, missing out on the capabilities of Azure							
в			Currently, product backlog reviews are done during design meetings and/or weekly issues			Sprint Planning	Risk	Medium	Open		1/26/2024	Gautam
		meetings can lead to unclear priorities, misalignment with	meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty		having conducted surveys and user group interviews in 2019 and 2020, is concerned							Gulvady
			in managing complexity, and delayed decision making.		that gathering feedback from a broader user base might lead to additional requests							
		scope creep.	A product backlog review is an essential part of agile project management, particularly in		without proper prioritization. DDD mentioned that the next product backlog meeting is							
			Scrum. It's a collaborative meeting where the Scrum team, including the Product Owner, Scrum Master, and development team members, inspect and adapt the product backlog.	be taken.	scheduled for Monday, 2/2/2025, due to current team availability and ongoing commitments. Additionally, IV&V will be invited to attend these backlog meetings.							
			Scrum Master, and development team members, inspect and adapt the product backlog.	IVV recommends scheduling separate dedicated product backlog review	communents. Additionary, read will be invited to attend these backlog meetings.							
			The product backlog review is an important Scrum ceremony that helps keep the backlog	meetings (during sprints) where all relevant stakeholders are invited to	12/31/24 -IV&V observed two CAMHD backlog prioritization meetings and will continue							
			relevant, up-to-date, and aligned with the project's goals and priorities. Here's a summary of		to monitor the process regularly. While CAMHD and DDD are generally satisfied with							
			what typically happens during a product backlog review:	that there is sufficient time to plan the design, development, and	the backlog prioritization, there are areas for improvement, particularly in balancing							
				implementation (DDI) of the next release(s).	input from a broader user base and ensuring that federal compliance and performance-							
1			1. Inspecting Backlog Items: The team reviews the items on the product backlog. This		related features are given appropriate attention in the backlog. By refining these		1	1				
			involves discussing each item, understanding its priority, value, and acceptance criteria.		aspects, both teams can improve the backlog prioritization process.							
			2. Ensuring Clarity: The team ensures that each backlog item is clear and well-understood.				1	1				
			Any ambiguities or uncertainties are clarified at this stage.		11/30/24 - The DDD team has scheduled a meeting for this month (November) to							
			3. Estimation: Estimation of backlog items may occur during the review. The team may use		review the product backlog. During this session, the team will assess the current							
			techniques like story points or relative sizing to estimate the effort required for each item.		backlog items, prioritize them according to business value and urgency, and ensure							
			 Re-prioritization: Based on new insights, changes in requirements, or stakeholder feedback, the team may need to re-prioritize items in the backlog. 		they align with the overall project goals. BHA plans to invite the IV&V team to participate in the backlog review meetings.							
			5. Removing or Adding Items: Items that are no longer relevant or necessary may be		participate in the backlog review meetings.							
			removed from the backlog. New items that emerge or are identified as important may be		10/31/24 - It has been confirmed that CAMHD holds bi-weekly product backlog review		1	1				
			added.		meetings to review and adapt the product backlog. DDD communicated that they							
			6. Refinement: Backlog refinement may also occur during the review. This involves breaking		conduct collaborative reviews as needed and is yet to adopt regular dedicated product		1	1				
			down large items into smaller, more manageable ones, or adding more detail to items as		backlog review meetings. IV&V recommends that DDD establish regular product		1	1				
			needed.		backlog review sessions to ensure consistent alignment with project goals and prioritize		1	1				
			7. Collaboration: The review is a collaborative effort involving the entire Scrum team. It's an		tasks effectively.							
			opportunity for open discussion and sharing of ideas to ensure everyone is aligned on the									
			goals and priorities.		9/30/24 - IV&V continues to recommend the development and use of a RACI matrix to		1	1				
			8. Updating Documentation: Any updates or changes made during the review should be		identify stakeholders who need to be involved in Sprint Reviews and product backlog		1	1				
			documented to ensure transparency and visibility for all stakeholders.		reviews. BHA and IV&V reviewed the RACI matrix, with IV&V providing feedback. BHA	1	1	1	1 I			
			9. Feedback Loop: The review often generates feedback that can be used to improve the		continues to refine and develop the RACI matrix to clearly define the roles and involve							

ID	Short Description	Finding Statement	Analysis and Significance	Recommendation	Finding Update	Category	Туре	Priority	Status Closed Date	Identified Date	Owner	
42	Governance	Lack of effective governance and communication among stakeholders can have significant negative impacts on a project in several ways.	Ineffective governance and communication among stakeholders can significantly impact a project in several ways, e.g., stakeholder disengagement, misunderstandings, conflict and tension, misalignment of objectives, increased risks, unclear roles and responsibilities, and quality issues. An example on this project is the development and implementation of Golden			Project Management	Issue	Medium	Open	2/29/2024	Gautam Gulvady	
			Record/Master Data Management (MDM). The lack of effective governance and communication among stakeholders can result in	contractual Terms & Conditions for the INSPIRE project. 2. Create a Governance Structure: Implement a governance structure that	indicate that BHA is utilizing additional User Story Points (USPs) to investigate and resolve defects from recent releases, such as R4.8. Based on earlier discussions with BHA, IV&V understands that a warranty period applies to such defects, meaning the							
			The last of elective governments and communication and the state inducts of an estimate project delays, budget overruns, and decreased quality. It's essential for project managers and stakeholders to prioritize clear communication and establish robust governance structures to ensure project success.	defines decision-making processes, escalation procedures, and accountability mechanisms. Clarify how decisions will be made, who has authority, and how issues will be resolved.	vendor should not charge BHA additional costs for their resolution. However, the SI has stated that there is no warranty period. URW and BHA will review the contractual terms and continue discussions in January 2025. The ultimate goal of this discussion is that all stakeholders have a common understanding of the current contractual terms.							
				3. Develop a Stakeholder Registry, RACI chart, and Stakeholder Engagement Plan: Identify key stakeholders and develop a plan to engage them throughout the project lifecycle. Tailor communication strategies to address the needs and preferences of different stakeholders, ensuring their active	conditions governing defect fixing and how defect fixing will be addressed in the future							
				involvement and support. 4. Clearly define Roles and Responsibilities: clearly outlining the roles and responsibilities of each stakeholder involved in the project, would ensure	10/31/24 - The lack of productive communication between DDD and CAMHD could leat to misunderstandings, confusion, unclear project priorities, and ultimately project delays. BHA is considering developing a documented governance process for restarting	8						
				responsionities of each sakehouder involved in the project, would ensure that everyone understands their duties and how they contribute to the project's success. 5. Encourage Open Communication and Feedback: Foster a culture of open	production systems. The project is considering various options for tracking costs of features that require a significant level of effort (project refers to these as "Big Rock" features).							
				communication and feedback where stakeholders feel comfortable sharing	9/30/24 - There remain some communication challenges between stakeholders on project aspects such as defect tracking and reporting, and tracking and monitoring cost related to Big Rock functionalities. IV&V recommends project teams maintain collaboration and information sharing across stakeholder groups to ensure shared	5						
				developments through regular updates and progress reports. Highlight achievements, challenges, and any changes to the project plan or scope.	understanding in key project areas. 8/31/2024 - There remain some communication challenges between stakeholders on							
				 Resolve Conflicts Promptly: Address conflicts and disagreements among stakeholders promptly and professionally. Encourage dialogue, active listening, and compromise to find mutually acceptable solutions that support 	project aspects such as defect tracking and reporting, and tracking and monitoring cost related to Big Rock functionalities. IV&V recommends project teams maintain collaboration and information sharing across stakeholder groups to ensure shared	5						
43	SharePoint folder performance.	Execution time for the process for updating DDD SharePoint folders was unacceptable.	The existing DDD SharePoint documents and folders update process is intensive and the execution time was unacceptable - this process took 11 calendar days to execute in	IV&V recommends doing an impact analysis, e.g., downstream impact.	1/31/25 - DDD is working to confirm final approvals to allow the digitization initiative to move forward with the SI, and the project may restart in Spring 2025. Meanwhile, DDD		Issue	Medium	Open	4/30/2024	Gautam Gulvady	
			production with R4.4. This process is part of several intense processes that update SharePoint documents and folders. The SI vendor recommended against doing this intensive process. However, no feasible alternative solutions were provided and this process was implemented.	IV&V recommends DDD puts on hold any development utilizing Power Automate for the performance issue encountered in production (marked "TBD" in finding #14 related to "SharePoint Bulk Flows still running"), related user stores, e.g., "Changes to DDD folders", and defects.	has paused further development on planned improvements to an existing process, which previously took approximately 16 days to complete, as the current SharePoint site cannot handle the anticipated volume of 2.5 million digitized documents without a redesign of its hierarchy.							
			BHA has the flexibility to refine and alter their SharePoint directory structure. As a result, per the SI vendor, the process does not pick up continuously evolving permutations of folder structures in Production, nor can the execution time be estimated or benchmarked. Per	IV&V recommends evaluating other feasible options, e.g., leveraging SharePoint tools and best practices. A project issue should be opened to identify and manage the resolution of	12/31/24 - DDD is working with stakeholders to determine the direction and next steps on the digitization initiative. 11/30/2024 – BHA plans to launch an initiative to digitize approximately 2.5 million							
			discussions between the SI vendor and BHA over many months, this process was not going to complete 100% of the operations because of the different folder structures in Production. And this process/lobs has been updated many times to address different folder structures that were captured during testing, but there is no guarantee that it covers every possible scenario - some cometations filled because the folder structure was not encountered during testing.	this issue.	paper documents as part of a broader effort to transition to a paperless system. While the SI has been working on enhancing the existing process which previously required around 15 days to complete, the current SharePoint site cannot accommodate the anticipated volume without a redesign of the SharePoint hierarchy. Considering the low frequency of the process (only once or twice per year) and the							
			testing, which was an expected event. The folders in Production that necessary steps to automate with Flow were supposed to be manually updated. The current solution utilizing Power Automate provided the necessary steps to automate		challenges posed by the SharePoint limitations, DDD has decided to pause further development on these improvements. However, if DDD encounters difficulties in executing the existing process, it will reevaluate the need for these enhancements.							
			this process, but it was never going to capture 100% of folders. And the process took 11 calendar days to execute in production.		10/31/24 - Development of the design improvements to create and rename folders for all existing customers in their SharePoint subsite will begin as higher priority user stories have been completed and a SharePoint resource becomes available. The new design will utilize PowerShell scripts, which are expected to be more efficient than the previously used Power Automate solution, which had slower-than-anticipated processing times.							
					9/30/24 - The development of the improvements will commence once a SharePoint resource is available.							
					8/31/2024 - The SI vendor has completed the design and stated that development of the improvements will commence once a SharePoint resource is available.							

ID	Short Description	Finding Statement	Analysis and Significance	Recommendation	Finding Update	Category	Туре	Priority	Status	Closed Date	Identified Date	Owner	
45	Cost tracking for big rocks	There is a lack of stakeholder alignment on cost tracking, federal financial participation allotments, and claims management.	The current process does not allow BHA to track actual costs versus budgeted costs of large functionality such as Provider Portal, Maui Wildfre Communication, Fast Health Interoperability Resources (FHR) or the Golden Record (GR). The absence of a clear process doesn't give insight into, e.g., how much of the budget has gone into developing functionality such as Provider Portal, Maui Wildfre Communication, FHR or GR functionality can better financial records and it would allow BHA to monitor costs of large functionality. By incorporating a clear process that would allow BHA to monitor costs of large functionality, BHA can maintain better financial records and it would allow BHA to track actual versus budgeted costs and answer questions, e.g., "how much money has been spent on developing Provider Portal, Maui Wildfire Communication, FHIR or Golden Record (GR) functionality?"	IV&V recommends that stakeholders establish a structured process to ensure alignment and guide resolution.	1/31/25 -: Discussions between IV&V, BHA, and Med-QUEST continue to address challenges in tracking federal financial participation allotments and managing claims submissions. Efforts are underway to define a structured process to guide resolution. 12/31/24 - BHA has escalated Med-QUEST's ongoing challenges with tracking federal financial participation allotments and managing its claims submission process to the appropriate personnel. The deployment of Fast Healthean Intercoperability Resources (FHIB) has been postponed, with a new target date of January 2025. IV&V remains concerned that scope creegi in FHI development could delay the implementation of other system features, potentially impacting system performance, reducing user productivity, and increasing user fustration. PCG, BHA, and Med-QUEST se having ongoing discussions to resolv Med-QUEST's challenges with tracking federal financial participation allotments and managing its claims submission process. 11/30/2024 - During earlier discussions between BHA and IV&V, DDD emphasized the importance of tracking costs for major functionalities lithe the Provider Portal and FHIR. In September 2024, IV&V proposed options for cost tracking, including the use of Tags in Azare DevOps (2010). BHA stateholders suggested animal straightforward methods, aligning with IV&V's recommendation. Since BHA is currently satisfied with the system rougetion. These definencies require considerable time to project's inception. These definencies require considerable time to make corrections and may require additional funding. Despite previous assumances of procedural improvements, the problem remains unresolved. 10/31/24 - Discussions about the options are ongoing. These options also enable tracking the allocation of a release's fixed number of User Story Points (USPs) across	Project Management	Issue	Medium	Open		5/25/2024	Gautam Gulvady	
					various categories or buckets by utilizing tags in Azure DevOps (ADO). IV&V is concerned that the extensive use of USPs to implement large-scale functionalities, such as FHIR, may result in the removal or reduction of planned features, which could impact system effectiveness, lower user engagement, and fall short of anticipated feature								
46	Defect management.	Neglecting the established defect management process could lead to lost/forgent enderets, user fururation, and could slow resolution of similar defects in the future.		IV&V recommends to: 1. Based on Best Practices, updating the defect management documentation and having regular refresher training on the defect management process. 2. Send communications to the project stakeholders to clarify the defect management process and the importance of logging all defects. 3. Take steps to assure current and new users understand how to report and/or log defects. 4. Consider designating a defect management lead or champion to oversee adherence to the process and assure all defects are logged. 5. Keep stakeholders informed about defect status, priority, imparts, and resolution timelines. This could increase awareness of the importance of logging defects. 6. Discuss ways to improve the defect logging and management process with the SI and come up with a plan to improve.	1/31/25 - During this reporting period, there continues to be a delay in creating tickets in Azure DevOgo (ADO) for defects. WWW remains concented about the project's deviation from the Defect Management process. IV&V, BHA and the SI will continue discussions to identify process gaps and determine next steps. 12/31/24 - During this reporting period, users encountered production issues related to the Calculator, including an inability to view active cases and resolved cases. However, the corresponding tickets were not promptly created in Azure DevOgs (ADO). IV&V remains concerned about the project's non-adherence to the Defect Management process. IV&V and BHA will continue discussions to identify process gaps and determine next steps. 11/30/2024 - In recent meetings with DDD and CAMHD, IV&V discussed the issue of some defects reported to the Helpdesk via phone or other channels not being logged or addressed. DDD noted that staff ind the process of logging such defects cumbersome. However, DDD leadership has emphasized that all defects must be logged. IV&V and BHA to continue these discussions to determine process gaps and the next steps. 10/31/24 - DOH leadership continues to express concerns that not all defects are being logged.	Project Management	Issue	Medium	Open		9/30/2024	Gautam Gulvady	
47	Production restarts.	The lack of a governance process for restarting production systems can impact service availability and frustrate end- users and hinder accountability.		and post-restart verifications.	1/31/25 - When an issue requiring a production Portal restart occurred only once, certain project stakeholders convened to discuss and implement the necessary steps. WeX recommends documenting the actions taken during that meeting as part of the process for production system restarts. Documenting processes and procedures removes ambiguity and ensures a common understanding among stakeholders. 12/31/24 - BHA suggested that the deployment team or the Help Desk team may be best suited to document the process. IV&V remains concerned that no further progress has been made and will continue to make recommendations on how BHA could resolve this issue and be prepared for a production restart. 11/30/24 - No progress has been made for this reporting period. 10/31/24 - BHA is considering developing a documented governance process for restarting production systems.	Project Management	Issue	Medium	Open		9/30/2024	Gautam Gulvady	
49	Unreported AERs and false positives.	Multiple AERs for a single episode and unresolved false positives could hinder CaseManager's ability to resolve unreported AERs.	SI has yet to demonstrate that multiple AERs are not created for a single episode and that an AER record should match an unreported AER record. These concerns arise from the use of claims data to identify unreported AERs and to address faise positives - events initially flagged as adverse but later determined not to be. If left unresolved, these issues could hinder the Case Managers' ability to effectively resolve unreported false positives. As Case Managers create AERs for unreported AERs, the number of unreported AERs should decrease. Currently, the solution tracks reported and unreported AERs but currently there is no way to simultaneously reduce unreported AERs and increase reported AERs.	IV&V recommends that the SI vendor validate the logic to address BHA's concerns.	1/31/25 -: The vendor has built the AER solution in accordance with project requirements and is actively working toward its completion. DDD has informed IV&V that the S1's AER team has successfully designed and demonstrated functional and visually appealing dashbaards. The AER solution has completed UAT and is being enhanced with new requirements to allow BHA to address unreported AERs or conduct reliable investigations. Key insights, such as trends in provider reporting of adverse events, the number of unreported AER disidentified, month-o-month tracking of unreported AERs, and which AERs were created for the unreported AERs, remain unavailable. Some new requirements will be ready by go-live, while others will be impremented posicilauch. To address these critical issues, the S1 and BHA are actively discussing potential improvements, including the creation of new user requests and user stories and	Project Management	Issue	Medium	Open		12/17/2024	Gautam Gulvady	

I	ID S	hort Description	Finding Statement	Analysis and Significance	Recommendation	Finding Update	Category	Туре	Priority	Status	Closed Date	Identified Date	Owner	
5	50 T	-	groupings, and access to training materials for the upcoming sessions.	BHA has requested the 31 for a complete updated AER project schedule which is yet to be delivered. It is essential for the project team to review training materials in advance to ensure they are properly aligned with the distinct needs of each trainee group. Given the differences in the users' dashboards, users will not be trained together, necessitating the reservation of specific times for each group. Furthermore, the Si vendor is prepared to engage in discussions and provide a preview of the materials that have already been developed. This preview will be valuable for refining content, ensuring it is relevant, and confirming that the materials meet the requirements of each user group.			Schedule Management	Preliminary Concern		Open		1/31/2025	Susmitha Rajan	